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“Life is not easy for any of us. But what of that? We must have perseverance and above all   
confidence in ourselves. We must believe that we are gifted for something, and that this thing, at 
whatever cost, must be attained.” 
/Marie Curie/ 
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CNQX  6-cyano-7-nitroquinoxaline-2,3-dione 
CREB  cyclic adenosine monophosphate response element binding protein 
CTF  C-terminal fragment 
EAATs  excitatory amino-acid transporters 
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ERK  extracellular signal-regulated kinase 
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Low Mg
2+
 ACSF low magnesium concentration-containing artificial cerebrospinal fluid 
LTD  long-term depression 
L-LTP  late phase of long-term potentiation 
LTP  long-term potentiation 
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III. INTRODUCTION 
3.1. GENERAL DESCRIPTION OF ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is the most prevalent form of dementia affecting mainly the elderly 
population. Estimates suggest that 36 million people were diagnosed with AD worldwide, and 
this number will double every 20 years (Lundkvist, Halldin et al. 2014). Not just the patients 
themselves, but their families and the society are also affected. The total costs of dementia were 
estimated to be $600 billion worldwide (Menting and Claassen 2014).  
AD was first described in a female patient by a German psychiatrist and neuropathologist, 
Alois Alzheimer in 1907 and the disease was named after him (Alzheimer, Stelzmann et al. 
1995). The main hallmarks of AD are the progressive cognitive impairment, behavioral changes 
and permanent loss of memory (De-Paula, Radanovic et al. 2012). Although AD is in the focus of 
intense research, no effective treatment is currently available.  
The disease is associated with early onset and progressive impairment in several brain areas 
having critical role in episodic memory, language and behavior (Weiner, Neubecker et al. 2008). 
It is estimated that the pathological process in AD brain begins at least 10-15 years before the 
first cognitive symptoms appear (Perrin, Fagan et al. 2009), including short-term memory loss 
and logopedic progressive aphasia (Magnin, Sylvestre et al. 2013). As the disease progresses, 
more severe memory loss and behavioral disturbances leading to confusion and lack of 
orientation occur (Mintzer, Mirski D et al., 2000). Two forms of AD can be distinguished, 
sporadic (SAD) and familiar (FAD), however they share common histological and clinical 
symptoms (Sassi, Guerreiro et al. 2014), and presumably common pathomechanisms. Two main 
neuropathological brain lesions are described in the brain tissues of AD patients: the extracellular 
accumulation of amyloid-beta (Abeta) and the intraneural neurofibrillary tangles (NFT) formed 
by hyperphosphorylated tau protein (Grundke-Iqbal, Iqbal et al. 1986).  
The heterogeneity of AD is evident in their clinical, anatomical and biological 
characteristics. Fisher and coworkers demonstrated neuropsychologically defined AD subtypes 
using CERAD for their work (Consortium to Establish a Registry for Alzheimer’s Disease) along 
with PET studies and classified the disease into five neuropsychological AD syndromes: typical 
AD, temporal (pure amnestic) variant AD, left (language) variant AD, right (visuoperceptive) AD 
and frontal (executive) variant AD (Fisher, Rourke et al. 1996, Fisher, Rourke et al. 1997, Lam, 
Masellis et al. 2013).  
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3.2. FORMATION OF AMYLOID-BETA PLAQUES 
3.2.1. THE AMYLOID CASCADE HYPOTHESIS 
Several factors can contribute to the pathogenesis of AD, however the exact mechanism is 
unknown. Soon after the discovery of AD-associated mutations in the amyloid precursor protein 
(APP) gene, the Abeta cascade hypothesis was postulated by John Hardy in 1992 that became the 
dominating hypothesis in the field (Hardy and Higgins 1992). The Abeta cascade hypothesis 
proposes that the deposition of Abeta in the brain is a crucial step in the development of AD. The 
hypothesis links histopathological and genetic properties that lead to development of Abeta 
depositions and AD dementia. 
Amyloid depositions are formed by Abeta peptides that derive from the much larger APP. 
APP is a widely expressed transmembrane glycoprotein and its gene is located on human 
chromosome 21 and expressed in several tissues (Lemmin, Dimitrov et al. 2014). It exists at least 
in ten isoforms, which are generated by differential splicing of exons 7 and 8, mainly APP695, 
APP751 and APP770 in the brain. In human cortex, the ratio of different APP isoforms is 
approximately APP695/APP751/APP770 = 20:10:1, however this ratio could change in different 
regions (Nalivaeva and Turner 2013). APP695 is the exon 7-skipped isoforms, and is most 
abundant in the neurons (LeBlanc, Chen et al. 1991), while APP751 and APP770 are expressed in 
glial cells (Kitazume, Yoshihisa et al. 2012). It was shown that Abeta was produced from APP695 
isoform via the cleavage of the APP intracellular domain by the action of β-secretase (Belyaev, 
Kellett et al. 2010), while another group suggests that Abeta could be released from APP770 by 
the actions of both α- and β-secretases in the endothelial cells of the brain (Kitazume, Tachida et 
al. 2010). APP plays a major role in the regulation of several important signaling pathways 
especially in the nervous system, such as synaptogenesis (Wang, Yang et al. 2005), axon 
elongation  (Chasseigneaux, Dinc et al. 2011) or iron export (Duce, Tsatsanis et al. 2010), 
however its basic physiological function is not fully clear.  
APP can be processed by secretases in two main pathways depending on the secretase that 
actually cleave it (reviewed by Vingtdeux, Sergeant et al. 2012). In the non-amyloidogenic 
pathway (Figure 1, left), α-secretase cuts APP within the Abeta sequence, releasing soluble 
secreted form of APP (sAPPα) and the membrane-associated C-terminal fragment (CTFα), which 
in turn is further processed by γ-secretase resulting in the release of the P3 peptide and amyloid 
precursor protein intracellular domain (AICD).  
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In the amyloidogenic pathway (Figure 1, right), APP is initially cleaved by β-secretase to 
generate a large soluble secreted form of APP (sAPPβ) and leaving the membrane-anchored C-
terminal fragment comprised of 99 amino-acid (CTFβ or C99). The intracellular sorting of β-
secretase is a critical step in APP processing (Chia, Toh et al. 2013). The subsequent action of 
CTFβ by γ-secretase releases Abeta peptide on the extracellular side, which produces Abeta 
species of 39-43 amino acids and the APP intracellular domain (AICD or C51) in the cytoplasm. 
It is noteworthy that AICD may have a potential gene expression regulatory function (Mattson 
2003). Furthermore, lysosomal processing of APP is a likely site of Abeta production (Tam, Seah 
et al. 2014). The γ-secretase complex is composed of presenilin (PSEN), nicastrin (NCT), γ-
secretase activating protein (GSAP), Pen-2 and Aph-1 proteins.  
 
Figure 1. Schematic representation of the two APP proteolytic pathways. APP may be cleaved in two 
distinct processes: non-amyloidogenic (left) and amyloidogenic (right). Alternative cleavage of APP by 
the α-secretase enzyme produces soluble, non-toxic compounds such as membrane-associated CTFα and 
sAPPα. In the amyloidogenic pathway, Abeta is released from the APP through the action of the β- and γ-
secretases. Abeta and AICD are produced by the γ-secretase cleavage of the CTFβ, which is then retained 
in the cytoplasmic membrane. Abbreviations: APP (amyloid precursor protein), CTF (C-terminal 
fragment), sAPP (soluble secreted form of amyloid precursor protein), Abeta (amyloid-beta) and AICD 
(amyloid precursor protein intracellular domain). Figure from Vingtdeux, Sergeant et al. 2012. 
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The hypothesis, that AD could be inherited in an autosomal dominant manner is further 
supported by research data. The disease-associated mutation that was first described is in the gene 
coding APP. More AD-associated mutations have been identified, such as the autosomal 
dominant mutations in presenilin 1 (PSEN1) and presenilin 2 (PSEN2), which induce increased 
activity of γ-secretase, causing a shifted balance towards amyloidogenic Abeta(1-42) versus 
shorter Abeta(1-40) or Abeta(1-38) species (Wanngren, Lara et al. 2014), and also disrupt the 
endoplasmic reticulum Ca
2+
 homeostasis (Schneider, Reverse et al. 2001). PSEN1 mutation is 
found in approximately 80% of cases of FAD (Sepulveda-Falla, Barrera-Ocampo et al. 2014).  
The apolipoprotein E (apoE) gene, which plays a role in the clearance of Abeta from the 
brain, was also shown as the major genetic risk factor for familial and sporadic AD. Three 
common apoE alleles have been described: apoE2, apoE3 and apoE4. The apoE4 allel has been 
consistently associated with AD, and this allel causes dysfunction of the lipid transport system 
and lipid homeostasis in the brain of AD patient (Guerreiro, Gustafson et al. 2012). 
3.2.2. DIFFERENT AGGREGATION FORMS OF AMYLOID-BETA 
Abeta, a misfolded protein, is widely regarded as a central player in the in the pathogenesis of 
AD. The accumulation of soluble Abeta(1-42) in the brain of patients and animal models of AD 
is associated with impairments of cognition and memory (Walsh, Klyubin et al. 2002). 
Progressive neuronal degeneration was also aggravated by membrane-associated oxidative stress 
induced by aggregation of Abeta (Mattson 2003). 
Abeta aggregation is a complex process, involving the misfolding of Abeta into soluble and 
insoluble forms. Monomeric Abeta is mainly composed of α-helical conformation, whereas the 
misfolded polymers are rich in β-sheet structures (Zhao, Chiu et al. 2012). It was shown that the 
soluble pool of Abeta may exist both at the extracellular and at the intracellular space (LaFerla, 
Green et al. 2007). Several studies have shown that misfolding of monomeric Abeta leads to the 
formation of oligomers, which then rapidly grow to larger polymers or fibrils (Ni, Shi et al. 2011, 
Zhao, Chiu et al. 2012).  
Two forms of amyloid plaques are distinguished in the AD brain: diffuse and senile, or 
neuritic plaques, which were originally described by Alois Alzheimer. Diffuse plaques are 
amorphous in their shape and are not surrounded by dying or damaged neurons (Joachim, Mori et 
al. 1989), however these deposits may be the precursors of fibrillogenesis (Pappolla, Omar et al. 
1992). Neuritic plaques have a diameter of around 50-200 µm; they contain a central core riched 
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in Abeta. It is often associated with axonal and dendritic injury and surrounding reactive 
astrocytes (McGeer, Itagaki et al. 1987). The major components of amyloid deposits are the 39-
43 amino acid-containing residues of Abeta peptide, which derive from the sequential cleavages 
of its precursor protein.  
The aggregation and deposition of Abeta in the brain is believed to be the link to the 
neuronal cell death and loss of cognitive function seen in AD. Although the fibrillated form of 
Abeta containing plaques is large, insoluble and more compact than the oligomers, the most toxic 
forms of Abeta are generally believed to be the soluble oligomers. The size of oligomer 
populations ranges from 8-22 KDa (low molecular weight) to 123-908 KDa (high molecular 
weight) (Fulop, Mandity et al. 2012). Evidence has been reported that both synthetic and brain-
derived human oligomer Abeta(1-42) are synaptotoxic, playing an essential pathogenic role in 
decreased spine density, damage certain forms of synaptic plasticity (Shankar, Bloodgood et al. 
2007, Selkoe 2008, Li, Hong et al. 2009, Fulop, Mandity et al. 2012). The oligomer Abeta-
induced long-term potentiation (LTP) inhibition can be rescued by the application of anti-Abeta 
antibodies in vivo (Walsh, Klyubin et al. 2002), suggesting that indeed Abeta is the primal 
synaptotoxic agent. The number of plaques does not correlate well with the severity of dementia  
(reviewed by Shankar and Walsh 2009), which suggest that the highly aggregated form of the 
peptide is nontoxic. On the other hand, the aggregated insoluble forms of Abeta may lead to later-
onset and more severe memory loss, associated with inflammatory reactions induced by fibrillar 
Abeta (Bamberger, Harris et al. 2003). Moreover, so-called “reverse oligomersˮ may dissociate 
from the plaques forming a halo of highly toxic Abeta forms around the plaque-core (Martins, 
Kuperstein et al. 2008, Koffie, Meyer-Luehmann et al. 2009). 
3.3. NEUROFIBRILLARY TANGLES 
Although the amyloid cascade hypothesis is the most widely accepted hypothesis that 
explains the development of AD, it does not consider the interaction of Abeta peptide with tau. 
Tau plays an essential role in regulating microtubule dynamics, axonal transport and neurite 
outgrowth (Biernat and Mandelkow 1999). These functions are modulated by site-specific 
phosphorylation of the tau protein (Hamdane, Sambo et al. 2003).  
It was reported that physiological assembly of the microtubule system in AD brain is 
disturbed by abnormally hyperphosphorylated forms of microtubule-associated tau protein 
forming intracellular NFTs. NFTs are formed by paired, helical ~10 nm filaments especially in 
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the hippocampal formation, amygdala, cortical and subcortical areas (reviewed by Selkoe 2011). 
The phosphorylated tau proteins are no longer able to stabilize the microtubules, which leads to 
disruption of neuronal transport and cause cell death (Baumann, Mandelkow et al. 1993). 
3.4. EXCITATORY SYNAPTIC TRANSMISSION IN THE CA1 
3.4.1. GLUTAMATERGIC SYNAPTIC TRANSMISSION 
The non-essential amino-acid, L-glutamate (Glu) is the major excitatory neurotransmitter in 
the mammalian central nervous system, and plays principal role in neural activation, especially in 
the cortical and hippocampal regions, which are associated with learning and memory (Dale and 
Kandel 1993, Staubli, Rogers et al. 1994). There are two large families of glutamate receptors 
(GluRs) located on the membrane of the neurons: ionotropic GluRs (iGluRs) and metabotropic 
GluRs (mGluRs), respectively. All of these receptors are comprised of 4 subunits forming a 
tetrameric structure (Willard and Koochekpour 2013). 
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) is an ionotropic 
transmembrane receptor, which has a lower affinity for Glu than the N-methyl-D-aspartate 
receptor  (NMDARs) (Patneau and Mayer 1990). AMPARs are the major mediators of Glu-
mediated fast excitatory synaptic transmission, are critical for the mediation of field potentials 
often used as an experimental readout for neuronal excitability (Bashir, Alford et al. 1991). The 
functional properties of the AMPARs are highly dependent on its subunit combinations. 
AMPARs lacking GluR2 subunit are permeable to Ca
2+
 (Wright and Vissel 2012).  
NMDARs are both ligand-gated and voltage-dependent, and their activation requires the 
simultaneous binding of Glu and either D-serine or glycine (Kleckner and Dingledine 1988). 
NMDAR activation also requires membrane depolarization, because either Mg
2+
 or Zn
2+
 ion 
blocks the pore of the channel under basal circumstances, and this blockade is voltage-sensitive 
(Low, Zheng et al. 2000). This type of receptor is a multimeric assembly of glycine- or D-serine 
binding NR1 and NR3A-B, as well as Glu-binding NR2A-D subunits and is predominantly 
permeable to Ca
2+
, in addition to Na
+
 and K
+
 (Laube, Kuhse et al. 1998, Awobuluyi, Yang et al. 
2007). Ca
2+
 influx via NMDARs triggers several cascade pathways that may alter synaptic 
efficacy and neuronal morphology. Of particular interest here, NR2A subunit-containing 
NMDARs localized mainly at the synaptic domain are antiapoptotic and participate in the 
induction of LTP in the CA1. In contrast, extrasynaptic NMDARs (esyn NMDARs) containing 
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mainly NR2B subunit (on pyramidal cells) were shown to activate apoptotic pathways and to 
promote synaptic depression (Hardingham, Fukunaga et al. 2002).  
Following presynaptic depolarization, vesicles may release their contents of Glu into the 
synaptic cleft by a highly Ca
2+
-dependent mechanisms. Glu can bind to GluRs of the post-
synaptic cell, initiating cation-flow, which depolarizes the post-synaptic neuron (Llinas, 
Steinberg et al. 1981). After Glu is released into the synaptic cleft, the unwanted Glu is cleared 
off by the Glu transporter systems. The released Glu requires extremely large number of Glu 
transporters. There are two Glu transporter systems in the brain: the vesicular Glu transporters 
(VGLUT) and the excitatory amino-acid Glu transporters (EAATs), both are abundantly 
expressed both in neuronal and glial cells in many regions of brain (Bar-Peled, Ben-Hur et al. 
1997). 
To prevent over-stimulation, EAATs bind Glu from the extracellular space and then undergo 
a conformational change which allows transportation of the Glu through the plasma membrane 
(Focke, Wang et al. 2013). The EAAT subtypes are expressed in different regions of the brain. 
EAAT1 and the most abundant transporter EAAT2 are expressed on glial cells of the 
hippocampus and cerebral cortex and responsible for 80-90% of all Glu transport (Rothstein, 
Dykes-Hoberg et al. 1996). Recent data also shows that the Glu uptake capacity of astrocytes is 
much higher than that of neurons (Proper, Hoogland et al. 2002). Furthermore, EAAT2 is also 
present on presynaptic side of the neuron (Yang, Gozen et al. 2009). EAAT3 is also highly 
expressed in these regions, most probably on post-synaptic side in neuronal cells (Popoli, Yan et 
al. 2012). EAATs-mediated Glu transport is Na
+
-dependent and is highly efficient even against a 
1000-fold concentration gradient (Attwell and Mobbs 1994). One Glu molecule is transported 
together with two or three Na
+
 ions and one H
+
 exchanges for one K
+
 ion. These transporters are 
regulated by protein kinases, growth factors and second messengers (Focke, Wang et al. 2013).  
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Figure 2. Glutamatergic synaptic transmission. During excitatory synaptic transmission, Glu is briefly 
released into the synaptic cleft, and then it binds to GluRs present mainly on the postsynaptic cell. The 
Ca
2+
 influx through NMDARs or AMPARs lacking GluR2, leads to activation of several molecular 
pathways such as CaMKII and ERK-MAPK stream which are critical to CREB phosphorylation and 
induction of LTP. However, other intracellular signaling can also be activated, which may lead to tau 
hyperphosporylation (GSK3β) and LTD (p38-MAPK). The normal physiological level of Glu is mediated 
by both neuronal and glial EAATs. Glu is transported via EAATs and transformed to glutamine by the 
glutamine synthase, then released into the extracellular space. The glutamine is taken into the presynaptic 
terminals and is converted into Glu by glutaminase. The produced Glu is packaged into vesicles via 
VGLUT. Abbreviations: Glu (glutamate), GluRs (glutamate receptors), NMDARs (N-methyl-D-aspartate 
receptors), AMPARs (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptors), CaMKII 
(Ca
2+
/calmodulin-dependent protein kinase II),  ERK (extracellular signal-regulated kinase),  p38-MAPK 
(p38-mitogen-activated protein kinase), CREB (cAMP response element binding protein), LTP (long-term 
potentiation), GSK3β  (glycogen synthase kinase 3β), LTD (long-term depression), EAATs (excitatory 
amino-acid glutamate transporters) and VGLUT (vesicular glutamate transporters). Figure from Campos-
Pena V and Meraz-Rios MA, Neurochemistry, 2014. 
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Without glial cells’ contribution, normal synaptic function of glutamatergic neurons is not 
possible involving development of learning and memory (Hertz and Zielke 2004). Recent data 
shows that the Glu uptake capacity of astrocytes is much higher than that of neurons (Proper, 
Hoogland et al. 2002). In addition, glial EAATs have high diffusion rate in the membrane: 
unbound transporters further away from the synapse can replace Glu-bounded closer to the 
synapse (Edwards 2015). Glial cells take up Glu through highly efficient EAATs and convert it to 
glutamine via the glutamine synthase pathway, then release glutamine into the extracellular space 
(see above, Figure 2).  
This mechanism is an essential contributor to normal Glu release from the neuron (Rothstein 
and Tabakoff 1984). The glutamine is taken up into the presynaptic terminals and metabolized 
into Glu by the mitochondrial phosphate-activated glutaminase enzyme. The produced Glu is 
packaged into synaptic vesicles by VGLUT. This process is highly dependent on the tight 
cooperation of synaptic terminals and glial cells (Campos-Pena and Meraz-Rios 2014). 
3.4.2. NEUROPLASTICITY 
The ability of synapses to change their efficiency is also known as synaptic plasticity. This 
mechanism is dependent on the pattern by which synapses are stimulated and by several 
neurotropic factors and modulators. LTP is the most studied form of long-term synaptic 
plasticity, which widely regarded as one of the major mechanism that might be the cellular basis 
of learning and memory (Teyler and Discenna 1984). LTP was first described in the rabbit 
dentate gyrus of the hippocampus by Terje Lømo and Timothy Bliss in 1973 (Teyler and 
Discenna 1984). Since its original observation, it has been also described in other brain 
structures, such as cerebral cortex, cerebellum and amygdala (Kimura, Nishigori et al. 1989, 
Clugnet and LeDoux 1990, Crepel and Jaillard 1991). In particular, NMDAR-dependent LTP in 
the CA1 is the most widely studied type of LTP, and there is evidence showing that this form of 
neuroplasticity is impaired in AD (reviewed by Selkoe 2008). In my thesis, I am focusing on the 
NMDAR-dependent LTP at the Schaffer-collateral pathway in the CA1. 
Two forms of LTP can be distinguished: early-phase of LTP (E-LTP) and late-phase of LTP 
(L-LTP). A weak, high frequency stimulation (single train of 100 pulses at 100 Hz) can trigger an 
increase in synaptic efficacy that lasts for about 1-2 hours, while triggering the L-LTP requires 
repeated, strong high frequency stimulation (multiple trains of 100 pulses at 100 Hz) that lasts for 
over 3 hours or even days (Figure 3, reviewed by Lu, Christian et al. 2008). However, Villers A 
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and her coworkers found that a single train of high frequency stimulation (100 Hz, 1 sec) also 
induces L-LTP (8 h) in mice hippocampal slices (Villers, Godaux et al. 2012). It is generally 
evidenced that the induction of E-LTP and L-LTP is very different, thus their biochemical 
pathways can lead to distinct changes in the synapses. E-LTP requires modification of various 
proteins and their trafficking at synapses, but is independent from gene transcription and protein 
synthesis, while L-LTP requires changes in gene expression and protein synthesis (Lu, Christian 
et al. 2008). However, it is also shown that L-LTP induced by a single train is independent from 
protein synthesis (Villers, Godaux et al. 2012).  
 
Figure 3. The timeline of the LTP phases. Panel A shows that a weak, high frequency stimulation can 
evoke an increase in synaptic efficacy (E-LTP), while triggering the L-LTP requires repeated, strong high 
frequency stimulation and dependent on gene transcription (B). The morphological changes in spines 
reduced over a long time (C). This figure also shows the activity-dependent secretion of BDNF at the 
presynaptic side (red in A and C) may require development of E-LTP and L-LTP (green in B and C). 
Abbreviations: LTP (long-term potentiation), E-LTP (early-phase of long-term potentiation), L-LTP (late-
phase of long-term potentiation) and BDNF (brain derived neurotrophic factor). Figure from Lu, Christian 
et al. 2008. 
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E-LTP involves Glu transmission and several postsynaptic processes that lead to enhanced 
Glu release from the presynapse and increased sensitivity to Glu on the postsynaptic side. When 
Glu is released from the presynaptic side onto the dendritic spine of the postsynaptic neuron, it 
can bind GluRs localised to the postsynaptic density (PSD) (reviewed by Byth 2014). The PSD 
involves iGluRs and several signaling proteins, and is linked to the actin filaments that support 
the structural framework of the spine. PSD contains NMDARs, which can enable Ca
2+ 
ion influx 
to the spine, and they require for a binding Glu and its coagonist. These coagonists, namely 
glycine or D-serine can bind to the NMDARs gating its activity, moreover they may play a role 
in astroglial regulation of neural plasticity (Fossat, Turpin et al. 2012). The activation of 
NMDARs requires Mg
2+
 ion removal from the channel. This occurs when there is a strong 
activation of nearby AMPARs, which can mediate rapid synaptic transmission. Moreover, Glu 
has to bind to NMDARs in the presence of depolarized postsynaptic membrane in order to 
activate the receptor (Bliss and Collingridge 1993). During LTP induction, nonsynaptic AMPARs 
are rapidly trafficked into the postsynaptic membrane, which is mediated by the activation of 
various protein kinases. Activated CaMKII phosphorylates the GluR1-containing AMPARs, 
increasing their sensitivity to Glu and increasing the synaptic expression of AMPAR (Lisman, 
Yasuda et al. 2012). CaMKII activation also induces remodeling of the cytoskeleton and 
functions as retrograde signal generator along with protein kinase C (PKC): a second messenger, 
namely nitrogen-oxide (NO) is released to the presynaptic terminal to increase the probability of 
neurotransmitter vesicle release (Johnstone and Raymond 2011). The activity-dependent brain 
derived neurotrophic factor (BDNF) released from presynaptic sites may also be necessary for E-
LTP and have a crucial role for L-LTP induction (see above, Figure 3).  
Elevated intracellular Ca
2+
 triggers CaMKII, which in turn activates adenylyl-cyclase and 
cAMP kinase, required for L-LTP. The increased Ca
2+
 influx via L-type voltage-dependent Ca
2+
 
channels (VDCC) is also critical for translation and for the activation of cAMP-mediated 
transcription (Morgan and Teyler 1999), while mitogen-activated protein kinase (MAPK) cascade 
can mediate cAMP response element binding protein (CREB) phosphorylation (Kanterewicz, 
Urban et al. 2000). The regulation of CREB has been shown to play a role in several protein 
kinases’ activation including protein kinase A (PKA), which may contribute to transcription via 
serum response element (SRE) by activating the ERK-MAPK stream (Adams, Anderson et al. 
2000, Davis, Vanhoutte et al. 2000). Protein synthesis occurs in dendrites too, and this type of 
local translation is necessary for L-LTP induction (Huang and Kandel 2005).  
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In summary, L-LTP differs from E-LTP in its requirement for gene transcription and in its 
association with structural and morphological changes at synapses. Induction of LTP results the 
functional and morphological development of synapses: the pre- and postsynaptic structures such 
as dendritic spines and axonal buttons are stabilized, the postsynaptic density via postsynaptic 
scaffolding proteins (PSD-95) are increased and also results enhanced postsynaptic sensitivity to 
Glu (Ehrlich, Klein et al. 2007). However, during induction and during E-LTP, the morphological 
changes of spine dynamics reduced progressively, and they are less stable over longer time 
(Yuste and Bonhoeffer 2001). The latter phase of LTP is associated with postranslational 
modifications that increase the excitatory postsynaptic current (EPSC). Moreover, presynaptic 
synthesis of synaptotagmin-1 and increased synaptic vesicle numbers suggest that protein 
synthesis is not restricted to the postsynaptic side (Ahmad, Polepalli et al. 2012). LTP induction 
also results in the growth of new spines, increased an dendritic spine number and formation of 
new synapses on the CA1 pyramidal cells. 
3.5. INVESTIGATION OF EXCITATORY EXTRACELLULARLY  
EVENTS IN THE CA1 
In my thesis I used multi-electrode electrophysiological recordings from hippocampal slices 
for investigating cellular events. Extracellular recording from hippocampal slices has long been a 
method of choice for determining the changes in excitability and synaptic plasticity of the CA1 
microcircuitry (Dingledine, Dodd et al. 1980).  
Spontaneous spikes and far more often, field excitatory postsynaptic potentials (fEPSPs) are 
recorded extracellularly from a local network of neurons, however, the relationship between these 
two phenomena is not fully clear. Intuitively, both electrophysiological events correlate with the 
excitability of the network under investigation, but these events are generated by different 
mechanisms. Evoked fEPSPs are mainly composed of subthreshold events from a population of 
neurons, like dendritic depolarizations (Tominaga, Tominaga et al. 2002) and glial contributions 
to the net extracellular charge-flow arising mainly from the function of transporters (Diamond, 
Bergles et al. 1998, Luscher, Malenka et al. 1998). In contrast, spontaneous firing represents only 
neuronal suprathreshold events (Brock, Coombs et al. 1952). Another difference is that a fEPSP 
is evoked by a stimulus, and therefore it is the result of a coordinated and synchronized electrical 
activity of a cell population mediated by synaptic connections. Spontaneous spikes, in contrast, 
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are not evoked by an external stimulus, and they are more likely to be dependent on intrinsic 
network connections and properties (Cohen and Miles 2000).  
Several protocols have been introduced to evoke LTP since its original description. By 
definition, NMDA-dependent LTP is a process of Hebbian synaptic plasticity, where input 
specificity, associativity, cooperativity, and persistence are the governing rules.  
3.6. AMYLOID-BETA INDUCES NEURONAL HYPEREXCITABILITY 
Seizures in patients with AD have been investigated by many researchers over the last 
decades. It was shown that AD patients can exhibit more than one spontaneous seizures, but the 
relationship of epilepsy and with AD pathophysiology has remained unknown (Rao, Dove et al. 
2009). Recent studies show that the occurrence of unprovoked seizures is 5-10-fold greater in 
SAD, and 87-fold greater in the less elderly cohort of patients (50-59 years old) than in the 
reference population (Amatniek, Hauser et al. 2006). Minkeviciene et al. have also demonstrated 
that Abeta-induced neuronal hyperexcitability culminates in epileptiform activity (Minkeviciene, 
Rheims et al. 2009). This fact shows that the brain network shifts towards hyperexcitability in 
AD, leading to several effects: neuronal dysfunction, cell death and cognitive decline. 
Importantly, this process enhances the production of Abeta, because Abeta release is dependent 
on the network activity (Cirrito, Kang et al. 2008, Kang, Lim et al. 2009).  
Several animal models were used to elucidate the relationship between AD and epilepsy. 
Numerous findings confirmed that excitotoxic effects of Glu contribute to progressive neuronal 
loss in AD (Koh, Yang et al. 1990, Pomara, Singh et al. 1992, Harkany, Abraham et al. 2000, 
Amatniek, Hauser et al. 2006). Alternations in Glu uptake regulatory system can lead to increased 
Glu level and subsequent increase in the excitability of the network. EAATs may be  central 
players in this mechanism, and indeed, recent findings suggest that Abeta oligomers inhibit 
normal Glu recycling at the synapse (Awobuluyi, Yang et al. 2007, Li, Hong et al. 2009, Chen, 
Reese et al. 2011), resulting in elevated ambient extracellular Glu level in the brain (Matos, 
Augusto et al. 2008, Mura, Zappettini et al. 2012), which might be responsible for the 
overexcitation seen in AD. Abeta blocks Glu reuptake by inhibiting both neuronal and glial 
EAATs (Li, Hong et al. 2009, Matos, Augusto et al. 2012), which might lead to esyn NMDAR 
activation. The activation of esyn NMDARs impairs LTP (Li, Jin et al. 2011), enhances LTD 
(Liu, Yang et al. 2013) and promotes apoptosis (Hardingham, Fukunaga et al. 2002). Recent 
findings suggest that Abeta binds to prion protein, mGluR5 and integrin receptors, and this 
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complex initiates a molecular cascade mediated by Fyn kinase (Larson, Sherman et al. 2012, Um, 
Nygaard et al. 2012, Um, Kaufman et al. 2013), which subsequently phosphorylates NMDARs. 
Increased phosphorylation of NMDARs enhances their sensitivity to Glu and modifies their 
opening kinetics.  
 
Figure 4. Effect of Abeta at multiple levels of complexity. Abeta causes failure of excitatory 
neurotransmission and impairs synaptic plasticity at the level of specific synapses (left). The hAPP-J20 
transgenic mice also show epileptiform activity and seizures at the network level (right). These results 
suggest that aberrant network synchronization is a primary effect of high Abeta level. Abbreviations: 
Abeta (amyloid-beta), hAPP-J20 (human amyloid precursor protein transgenic mice), F (frontal), fEPSPs 
(field excitatory postsynaptic potentials), H (hippocampal), L (left), NTG (nontransgenic mice), O 
(posterior-parietal), P (parietal), R (right), T (temporal), TBS (theta-burst stimulus). Figure from Palop 
and Mucke 2009. 
The brain can be described as a complex system of networks and is classified by multiple 
levels of complexity. Molecular and synaptic alternations can influence the network function in 
higher levels manifesting in rhythmic neural activity. It is well characterized that Abeta interferes 
with excitatory neurotransmission at synaptic level, however its effect on the network is still 
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undetermined. Figure 4. is a good summary of the effect of Abeta on synaptic transmission and 
on the network (see above, Figure 4) (reviewed by Palop and Mucke 2009). The authors have 
shown that paired-pulse ratio (PPF) and LTP was depressed in human APP (hAPP) expressing 
transgenic mice, as well as these mice also exhibited frequent generalized cortical epileptiform 
spike discharges that may lead to cognitive deficit (Palop, Chin et al. 2007). Although, their 
experimental data also show that the excitatory transmission was reduced in the hippocampus of 
transgenic mice, epileptiform activity was recorded from both hippocampal and cortical regions 
of the same mouse strain. 
3.7. THERAPEUTIC APPROACHES IN ALZHEIMER’S DISEASE: FOCUSING ON 
GLUTAMATE TOXICITY AND THE SCAVENGER SYSTEM 
Several studies have clearly indicated that Abeta toxicity is mediated by Glu excitotoxicity, 
involving Glu spillover and esyn NMDARs activation, excessive Ca
2+
 influx and consequent 
activation of cascade pathways resulting in cell death. Thus, Glu plays a critical role in Abeta 
pathology, therefore GluR antagonists could be promising therapeutic targets against AD.  
Currently, the only drug that targets the Glu system and is used for treating AD in the clinic 
is memantine, a non-competitive NMDAR antagonist. This compound exhibits higher affinity to 
NMDARs than the endogenous NMDAR antagonist, Mg
2+ 
ion (Chen, Pellegrini et al. 1992). 
Memantine can attenuate the excessive Ca
2+
 flow into the cell without interfering with normal 
physiological processes. It was also shown that memantine favorably binds to and blocks 
NMDARs during its prolonged activation, however this process takes place during a few 
milliseconds, thus memantine is not able to act or accumulate in the channel under normal 
synaptic activity (reviewed by Revett, Baker et al. 2013). Furthermore, it was also shown that 
memantine is able to reverse Abeta-induced LTP damage (Klyubin, Wang et al. 2011), reduces 
Abeta plaque number and increases synaptic density in a mouse model of AD (Dong, Yuede et al. 
2008). Despite these findings, the clinical efficiency of the drug is still debated (Schneider, 
Dagerman et al. 2011). 
Increased extracellular Glu level may activate esyn NMDARs leading to neuronal 
overactivation and cell death. More recently, Abeta-induced neuronal hyperexcitability via esyn 
NMDARs has been suggested to play a critical role in hyperexcitation (Costa, Lacor et al. 2012, 
Koeglsperger, Li et al. 2013). Indeed, p38-MAPK pathway is altered by Abeta resulting in LTD 
facilitation via both esyn NMDARs and mGluRs (Chen, Lin et al. 2013). Moreover, blocking 
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NR2B subunits by ifenprodil or Ro-6981 rescued Abeta-induced LTP disruption (Li, Jin et al. 
2011, Zhang, Wang et al. 2013), suggesting that it might be a potential therapeutic target against 
AD. Indeed, recent papers have suggested that memantine itself has greater affinity for esyn 
NMDARs that to synaptic NMDARs (Xia, Chen et al. 2010). 
It is also likely that Abeta increases extracellular Glu levels by damaging the function of Glu 
transporters. Jacob et al. have found that gene expression and protein levels of EAATs are altered 
in AD brains, especially in the hippocampus and frontal cortex (Jacob, Koutsilieri et al. 2007). 
This suggests that by restoring the normal level of EAAT in the brain, a possible protection can 
be reached. Interestingly, ceftriaxone, a β-lactam antibiotic was shown to have a side effect that 
increases the expression of EAATs in the brain (Rothstein, Patel et al. 2005), and this might be 
exploited as a treatment against AD. 
Another approach might be to reduce brain Glu level through the BBB. The blood Glu level 
is regulated by two Glu transaminases, glutamic-pyruvic transaminase (GPT) and glutamic-
oxaloacetate transaminase (GOT). These enzymes play a critical role in reducing Glu levels in the 
blood by converting Glu into other molecules along with their substrates, pyruvate (Pyr) and 
oxaloacetate (Oxa) (Figure 5) (Palmada and Centelles 1998). If the blood Glu level is decreasing, 
the EAATs localized on the brain capillaries can pump out the excess Glu from the CNS with 
higher efficiency. 
 
Figure 5. Glu metabolism. Glu can be converted to alanine and α-ketoglutarate (by GPT) or aspartate and 
α-ketoglutarate (by GOT) by reversible mechanism in the brain. These processes require the substrates of 
the enzymes. Abbreviations: Glu (glutamate), glutamic-pyruvic transminase (GPT) and glutamic-
oxaloacetate transminase (GOT).  
It was shown that the intravenous administration of either Pyr or Oxa decreases blood Glu 
level and subsequently reduces brain Glu concentration (Teichberg, Cohen-Kashi-Malina et al. 
2009, Boyko, Stepensky et al. 2012). Based on this fact, blood Glu scavenger system was 
proposed by Vivian Teichberg as a new approach for the treatment of neurological conditions 
associated with excitotoxicity (Zlotnik, Gurevich et al. 2007). Indeed, these Glu scavengers have 
protective effect in several disorders, such as traumatic brain injury (Zlotnik, Gurevich et al. 
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2007), stroke (Castellanos, Sobrino et al. 2008), ischemia (Marosi, Fuzik et al. 2009) and 
neuropathy (Nie and Weng 2010). We suggest that this method may be a promising treatment 
against AD. Indeed, GPT could prevent Abeta-induced LTD enhancement in a slice experiment 
without affecting baseline synaptic activity (Li, Hong et al. 2009). Moreover, application of a Glu 
uptake inhibitor mimicked the action of Abeta on LTD enhancement, indicating that Abeta 
oligomers perturb synaptic plasticity by altering Glu recycling (Li, Hong et al. 2009).  
Based on these findings, we aimed to investigate further the connection between Glu 
homeostasis and Abeta-induced synaptic plasticity impairment. 
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IV. AIMS 
There is growing evidence that Abeta oligomers mediate synaptic impairment in AD, 
however the exact mechanism of synaptic depression is still unknown. 
My Ph.D. work aims to identify a possible pathway of increased neuronal excitability and 
impaired synaptic plasticity caused by Abeta(1-42) using electrophysiological recordings by a 
multi-electrode array setup.  
We aimed to clarify the following points: 
1) Is there a difference between the mechanism of evoked and spontaneous neuronal 
events? 
2) Which receptors are involved in the generation of fEPSP and spontaneous spiking 
activity? 
3) How does Abeta influence evoked and spontaneous neuronal activity? 
4) Can we mimick the effect of Abeta by blocking Glu reuptake? 
5) Can we prevent the effect of Abeta by reducing the extracellular Glu level in the brain? 
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V. MATERIALS AND METHODS 
5.1. COMPOUNDS 
For the preparation of artificial cerebrospinal fluid (ACSF), all salts, glucose, 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX), (+)-MK801 hydrogen maleate (MK801), α-(4-
hydroxyphenyl)-β-methyl-4-benzyl-1-piperidineethanol (+)-tartrate (ifenprodil), sodium pyruvate 
(Pyr), GPT and DL-threo-β-benzyloxyaspartate (TBOA) were purchased from Sigma-Aldrich (St 
Louis, MO).  
5.2. ANIMALS 
The study conformed to EU Directive 2010/63/EU and was approved by the regional Station 
for Animal Health and Food Control under Project License XVI/8/2013. BALB/c mice were 
housed in groups of 2-3 under standard conditions (24°C, 12 h light-dark cycle) with food and 
water available ad libitum.  
5.3. EX VIVO ELECTROPHYSIOLOGY 
5.3.1. EXTRACELLULAR RECORDING USING MULTI-ELECTRODE ARRAY 
Transverse acute hippocampal slices of 400 µm in thickness were prepared from the brains 
of 3 month old mice using a McIlwain tissue chopper (Campden Instrument, Loughborough, 
UK). Slices were incubated in ACSF gassed with 95% O2, 5% CO2 at 35°C for 60 min. ACSF 
was composed of (in mM): 130 NaCl, 3.5 KCl, 3 CaCl2, 1.5 MgSO4, 0.96 NaH2PO4,  
24 NaHCO3 and 10 D-glucose, pH 7.4. Individual slices were transferred to a 3D multi-electrode 
array (MEA) chip with 60 tip-shaped and 60 µm high electrodes spaced by 200 µm (Qwane 
Biosciences, Lausanne, Switzerland, Figure 6). The surrounding solution was removed quickly, 
and the slice was immobilized by placing a grid onto it. The slices were continuously perfused 
with oxygenated ACSF (3 ml/min at 36°C) throughout the entire recording session. Data were 
recorded using a standard, commercially available MEA 60 setup (Multi Channel Systems MCS 
GmbH, Reutlingen, Germany).  
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Figure 6. 3D tip-shaped MEA60 biochip. MEA biochips are realised on small glass substrate that consist 
of micro-fabricated platinum electrodes that are used to measure electrical activity from hippocampal 
slices (left). Middle figure shows the schematic array of the chip. The tip-shape electrodes penetrate 
through the upper outer dead cell layer of the slice thereby enabling to record signals that come from 
healthy neurons in the deeper layer of the slice (right) (Qwane Biosciences, Lausanne, Switzerland). 
Abbreviation: MEA (multi-electrode array). 
5.3.2. STIMULATION PROTOCOL AND DATA ANALYSIS 
Care was taken to place the stimulating electrode in the same region at every slice. The 
Schaffer-collateral was stimulated by injecting a biphasic voltage waveform (−100/+100-µs) 
through one selected electrode at 0.033 Hz. Evoked fEPSPs were recorded from the proximal 
stratum radiatum at 10 kHz (Figure 7A), while spontaneous spiking activity from the stratum 
pyramidale in the CA1 at a frequency of 25 kHz for 5 min epochs (Figure 7B). After a 30 min 
incubation period, the threshold and maximum stimulation intensities for evoked responses were 
determined. To evoke responses, 30% of the maximal stimulation intensity was used. For 
analyzing the peak-to-peak amplitudes of fEPSPs MC_Rack program, while for sorting and 
analyzing the spiking activity, Spike2 software package (Cambridge Electronic Design, 
Cambridge, UK) was used. Evoked fEPSPs recordings were filtered above 10 Hz, while 
spontaneous activity was filtered between 300-3000 Hz offline.  
Before any treatment, fEPSPs were recorded for 1 hour followed by a 5 min spike recording 
(0 h). Electric stimulation was ceased during spontaneous activity recordings. After  
30 min treatment, spiking activity was also recorded, and the number of spikes after treatment 
(1.5 h) was normalized to the initial firing activity (0 h). On the other hand, the level of evoked 
fEPSPs (the last 10 peak-to-peak amplitudes) was compared to the average of the 20 peak-to-
peak amplitudes of the control level in all cases (Figure 8A). 
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Figure 7. Exemplar recordings in the CA1. Both evoked fEPSPs and spiking activity recording 
electrodes were located in the CA1 region of a mouse hippocampal slice. The fEPSPs were recorded from 
the proximal stratum radiatum (A) and the spontaneous spiking was recorded from the stratum 
pyramidale (B). Both fEPSPs and spiking activity were recorded from the same slice. Data were 
considered as multi-unit activity. Abbreviation: fEPSPs (field excitatory postsynaptic potentials). 
In the other groups, which were treated with Abeta, spontaneous activity was recorded before 
treatment (0 h) followed by 25 min fEPSPs recording, than spiking activity was also recorded for 
5 min (0.5 h). Number of spikes was normalized to the initial firing activity (0 h), which was 
taken as 100% in all channels. The threshold for spike detection was set to 2.5-fold of noise 
level. The data of those electrodes were included in the analysis where the initial spiking activity 
was above 0.5 Hz. Firing activity ranged from 150 to 1000 spikes/5 min. Data were considered 
as multi-unit activity. Field EPSPs were recorded for 25 min, followed by a 5 min spiking 
recording, then again fEPSPs were recorded. The level of evoked fEPSPs (the last 10 peak-to-
peak amplitudes) was compared to the control level in all cases (Figure 8B). 
In a second set of experiments, where we focused on LTP, slices were treated for 1 h before 
inducing LTP. The level of LTP (the last 10 peak-to-peak amplitudes) was compared to the 
average of the last 20 peak-to-peak amplitudes of evoked fEPSPs before applying theta-burst 
stimulation (TBS). TBS comprised of 15 trains administered at 5 Hz, the individual trains 
contained 4 pulses separated by 10-ms (Figure 9). 
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Figure 8. The timeline of the experiments. The fEPSPs were recorded from the proximal stratum 
radiatum and the spontaneous spiking was recorded from the stratum pyramidale. Before any treatments, 
slices were left to incubate for 60 min (grey line), then they were applied (black line). The effect of 
CNQX was also investigated in Low Mg
2+
 ACSF (middle panel). In this set of experiment, the last 10 min 
of the incubation period was the control level (dashed line) (A). In the other groups, following 10 min 
control level, slices were applied both Abeta(1-42) and ifenprodil for 2.5 h, and the spiking activity was 
recorded at every 30 min for 5 min (B). Abbreviations: fEPSPs (field excitatory postsynaptic potentials), 
GluRs (glutamate receptors), Abeta(1-42) (amyloid-beta(1-42)), AMPA (α-Amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid), NMDA (N-methyl-D-aspartate), CNQX (6-cyano-7-nitroquinoxaline-2,3-
dione), Low Mg
2+
 ACSF (Low Mg2SO4-containing ACSF), MK801 ((+)-MK801 hydrogen maleate) and 
ifenprodil (α-(4-hydroxyphenyl)-β-methyl-4-benzyl-1-piperidineethanol (+)-tartrate). 
5.3.3. DRUG TREATMENTS 
All slices were incubated for 30 min without stimulation in the recording chamber before any 
recording was done. Following the first spike-recording (0 h), slices were left to incubate a 
further 60 min with continuous electric stimulation, then slices were applied with 10 µM CNQX 
or 10 µM MK801 or 25 µM MK801 or ACSF containing low concentration of Mg2SO4 (Low 
Mg
2+
 ACSF; 0.25 mM) or 0.5 µM NMDA or 0.05 µM AMPA for 30 min (Figure 8A). 
Spontaneous spiking was recorded before and 30 min after the 5 min treatment epochs. The 
effect of CNQX was also tested in Low Mg2SO4-containing ACSF (0.25 mM), where modified 
ACSF was perfused to the slices from the beginning of the experiment. 
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Other cohorts of slices were treated with 1 µM oligomer Abeta(1-42), ifenprodil (3 µM) and 
ifenprodil+Abeta(1-42) for 2.5 h. The spiking activity was also recorded at every 30 min for 5 
min (Figure 8B). 
Next, slices were treated with 1 µM oligomer Abeta(1-42) for 60 min, then LTP was induced 
by the TBS protocol. LTP was followed for 1.5 hour after TBS. During treatment, evoked 
fEPSPs were recorded. In the other hand, after 10 min control level, slices were treated with 1 
µM Abeta(1-42) or 5 µM TBOA for 60 min before LTP was induced (Figure 9). Another cohort 
of slices was treated with 3 µM ifenprodil or 0.82 mM Pyr for 10 min then 2.06 U/ml GPT for 60 
min before LTP induction. Separate groups of slices were treated with these compounds together 
with Abeta(1-42) or TBOA. 
 
Figure 9. The timeline of the LTP experiments. Evoked fEPSPs were recorded from the proximal 
stratum radiatum. After 10 min control level (grey line), slices were applied different treatments for 60 
min (black line), then LTP was evoked by TBS and was followed for 90 min. Abbreviations: LTP (long-
term potentiation), fEPSPs (field excitatory postsynaptic potentials), TBS (theta burst stimulus), 
ifenprodil (α-(4-hydroxyphenyl)-β-methyl-4-benzyl-1-piperidineethanol-(+)-tartrate), Abeta(1-42 
(amyloid-beta(1-42)), TBOA (DL-threo-β-benzyloxyaspartate), Pyr (sodium pyruvate) and GPT 
(glutamic-pyruvic transaminase). 
5.4. STATISTICS 
Testing for normality was done with the Kolmogorov-Smirnov normality test. Our fEPSPs 
data have shown normal distribution, hence independent samples t-test and one-way repeated 
measures analysis of variance (ANOVA) was used with the Bonferroni test for post-hoc analysis.  
Despite of this, spiking data have shown nonparametric distribution, thus we used 
nonparametric tests (Kruskal-Wallis test was followed by Mann-Whitney U-test) for determining 
differences between two and several groups.  
The p value ≤0.05 was considered significant in all cases. Data were analyzed using SPSS 
statistical software.  
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5.5. SYNTHESIS AND CHARACTERIZATION OF AMYLOID-BETA 
Detailed description of the synthesis and characterization of Abeta(1-42) is reported in Bozso 
and his coworkers and in Fulop and her coworkers (Bozso, Penke et al. 2010, Fulop, Mandity et 
al. 2012). To summarize shortly, a depsipeptide derivative of Abeta(1-42) was synthesized and 
after purification, it was used in lyophilized form. A 200 μM stock solution of the peptide was 
prepared in 0.1 mM NaOH, and the pH was set to 11.0. After incubation for 2 hour at ambient 
temperature, the stock solution was diluted into ACSF to a concentration of 50 μM and the pH 
was set to 7.3. The peptide solution was incubated for 12 hour at 37°C and prior to use, it was 
diluted with ACSF to a final concentration of 1 μM.  
Aggregation grade and the size distribution of the oligomers were checked by Western Blots 
(WB) by following the methods described in Fulop, Mandity et al. 2012. Oligomers were 
detected either with sequence-specific BAM10 antibodies (Sigma-Aldrich), or with conformation 
specific OC antibodies (Millipore), which detects the oligomers of fibrillar nature, i.e. of beta-
sheet structure. 
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VI. RESULTS 
6.1. EVOKED FIELD POTENTIALS, BUT NOT SPONTANEOUS SPIKES  
ARE MEDIATED BY AMPA RECEPTORS 
Evoked fEPSP are regarded as the input, while spiking rate as the output of the neuronal 
network; however, the relationship between these two phenomena is not fully clear. We recorded 
fEPSPs from the proximal stratum radiatum (see above, Figure 7A) and in parallel spontaneous 
spikes from the stratum pyramidale (see above, Figure 7B) of the CA1 using MEA electrodes. 
Both fEPSPs and spontaneous activity could be abolished by application of 1 µM tetrodotoxin 
(data not shown).  
First, we investigated the contribution of AMPARs to evoked fEPSPs and spontaneous 
activity using CNQX (10 µM), an AMPAR inhibitor. Blocking AMPARs resulted in a complete 
reduction of evoked fEPSPs (untreated: n=5; 98.84±2.41% vs. CNQX: n=5; 4.62±0.45%, 
p<0.001, independent samples t-test; Figure 10A,B). Conversely, spontaneous activity remained 
unaffected (untreated: n=5; 139.55±44.95% vs. CNQX: n=5; 182.18±56.76%, Mann-Whitney U-
test; Figure 10C), suggesting that AMPARs have a key role in generating fEPSPs, but not 
spiking activity. 
Under physiological conditions, NMDARs activation is dependent on depolarization, e.g. on 
previous AMPARs activation (Bliss and Collingridge 1993). Thus we changed to Low Mg
2+
 
ACSF (0.25 mM) to remove the depolarization-dependent Mg
2+
 plug from the NMDARs 
(Derchansky, Shahar et al. 2004). Consistent with our previous findings, applying CNQX in Low 
Mg
2+
 ACSF for 30 min, fEPSPs were completely abolished (untreated: n=7; 101.54±1.69% vs. 
CNQX in Low Mg
2+
 ACSF: n=6; 6.44±0.36%, p<0.001, independent samples t-test; 
Supplementary Figure 1), suggesting that CNQX-inhibited fEPSPs are independent from 
NMDARs activation. 
We have also tried to activate AMPARs by applying a low concentration of AMPA (0.05 
µM), but we observed epileptiform field responses and a huge elevation of basal activity which 
hindered the unambiguous detection of action potentials (Supplementary Figure 2).  
These findings suggest that evoked fEPSPs, but not spontaneous spikes require AMPARs 
activity.  
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Figure 10. AMPARs regulate mainly fEPSPs but not spontaneous spikes. Panel A shows the changes 
of fEPSPs amplitudes over time: blocking AMPARs completely inhibited fEPSPs compare to untreated 
slices. The upper panel shows representative fEPSPs before (b) and after (a) treatment. Bar graphs 
represent the average of the fEPSPs amplitudes of the 25-30 min period after treatment (B). CNQX 
induced a complete reduction of evoked fEPSPs (n=5, p<0.001), however the spontaneous activity was 
not affected (C). Above panel C, superimposed representative spontaneous activities. Error bars represent 
SEM; ***p≤0.001. Abbreviations: fEPSP (field excitatory postsynaptic potential), AMPARs (α-Amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptors) and CNQX (6-cyano-7-nitroquinoxaline-2,3-
dione). 
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6.2. SPONTANEOUS FIRING, BUT NOT FIELD POTENTIAL  
IS GOVERNED BY NMDA RECEPTOR FUNCTION 
Next, we focused on NMDARs to test how the modulation of these receptors affect both 
evoked fEPSPs and spiking activity. Applying an NMDAR antagonist, MK801 did change 
evoked fEPSP amplitudes in neither 10 µM nor in 25 µM (untreated: n=5; 98.8±2.4% vs. MK801 
in 10 µM: n=5; 101.23±1.17% vs. MK801 in 25 µM: n=5; 104.49±1.72, one-way ANOVA, 
Bonferroni post-hoc test; Figure 11A,B). In contrast, MK801 caused a dose-dependent inhibition 
of spiking rate (untreated: n=5; 139.55±44.95% vs. MK801 in 10 µM: n=5; 96.73%±32.22, 
p=0.48 vs. MK801 in 25 µM: n=5; 29.23±22.93, p=0.035, Mann-Whitney U-test; Figure 11C).  
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Figure 11. NMDARs influence spontaneous spiking but not fEPSPs. Panel A shows the changes of 
fEPSPs amplitudes over time and the upper panel depicts representative fEPSPs before (b) and after (a) 
treatments. Blocking (MK801) or enhancing (Low Mg
2+
 ACSF) NMDAR function did not change the 
fEPSPs amplitudes. Bar graphs represent the average of the fEPSPs amplitudes of the 25-30 min period 
after treatments (B). MK801 dose-dependently reduced spiking frequency, while Low Mg
2+
 ACSF 
increased firing rate (untreated vs. MK801 in 25 µM: p=0.035 and untreated vs. Low Mg2+ ACSF: 
p=0.004) (C). Representative spikes are shown at the left from the respective groups. Error bars represent 
SEM; *p≤0.05 and **p≤0.01. Abbreviations: NMDAR (N-methyl-D-aspartate receptor), fEPSPs (field 
excitatory postsynaptic potentials), MK801 (+)-MK801 hydrogen maleate) and Low Mg2SO4 ACSF (low 
Mg2SO4-containing artificial cerebrospinal fluid). 
Next, we tried to enhance NMDAR function. We have supposed that removal the 
depolarization-dependent Mg
2+
 plug from the NMDARs may induce elevated spiking activity 
without any effect on evoked fEPSPs. Indeed, Low Mg
2+
 ACSF induced a massively elevated 
frequency of the spontaneous activity compared to the untreated slices (n=7, 316.34±41.89%, 
p=0.004, Mann-Whitney U-test; Figure 11C), but evoked fEPSP responses remained unchanged 
(n=7, 101.54±1.69%, one-way ANOVA, Bonferroni post-hoc test).  
Based on these results we hypothesized that spontaneous firing is mediated by the ambient 
Glu concentration acting on the esyn NMDARs.   
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Figure 12. NMDA induces a trend of elevated firing rate without affecting fEPSPs. Figure A 
represents the change of fEPSP amplitudes and the upper panel shows raw fEPSPs before (b) and after (a) 
treatment. Small concentration of NMDA (0.5 µM), which was reported to activate esyn NMDARs, did 
not affect fEPSPs. Bar graphs show the average of the fEPSPs amplitudes of the 25-30 min period after 
treatment (B). Low concentration of NMDA elevated spiking frequency, although not significantly (C). 
Left panel shows exemplar spikes from the respective group. Error bars represent SEM. Abbreviations: 
esyn NMDAR (extrasynaptic N-methyl-D-aspartate receptor) and fEPSPs (field excitatory postsynaptic 
potential). 
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Therefore, we tried to activate selectively this set of receptors by applying low concentration 
of NMDA (0.5 µM) in normal ACSF (Harney, Jane et al. 2008). This treatment resulted in 
unaltered fEPSPs (untreated: n=5; 98.8±2.40% vs. NMDA: n=9; 94.03±1.04%; independent 
samples t-test; see above, Figure 12A,B), but influenced spiking activity (untreated: n=5; 
139.55±44.95% vs. NMDA: n=9; 253.02±105.9%, p=0.51, Mann-Whitney U-test; Figure 12C). 
This change is almost significant, thus low concentration of NMDA induced a trend of elevated 
firing rate.  
These various findings suggest that evoked fEPSPs are mediated by AMPARs, but 
spontaneous spiking mainly requires esyn NMDARs activity. 
6.3. AMYLOID-BETA(1-42) INDUCES HYPEREXCITATION VIA NR2B 
Excessive neuronal activity is a phenomenon associated with early AD, however underlying 
mechanisms are not well understood. After establishing that fEPSPs and spontaneous firing are 
mediated by distinct set of receptors, we tried to investigate the effect of Abeta(1-42) on evoked 
fEPSPs and spontaneous activity. Spiking rate was determined every 30 min in 5 min epochs 
within the time frame of the recordings.  
In the untreated slices the amplitude of fEPSPs increased slightly until 1.5 h reaching 
103.36±2.67% of the initial amplitude, then decreased to initial value (n=5; 0.5 h: 100.8±1.65%; 
1 h: 102.9±1.84%; 2 h: 100.86±3.38% and 2.5 h: 98.18±4.04%, one-way repeated measures 
ANOVA, Bonferroni post-hoc test; Figure 13). Similarly, spiking frequency did not change over 
time (n=5; 0.5 h: 124.34±29.72%; 1 h: 129.57±53.28%; 1.5 h: 139.55±44.95%; 2 h: 
102.48±28.42 and 2.5 h: 76.16±28.08%, Mann-Whitney U-test; Figure 14).  
Abeta(1-42) applied in 1 µM did not change fEPSPs amplitudes (Abeta(1-42): n=7; 0.5 h: 
107.08±2.43%; 1 h: 106.41±2.93%; 1.5 h: 103.54±3.07%; 2 h: 100.92±3.06% and 2.5 h: 
97.1±2.97%, one-way repeated measures ANOVA, Bonferroni post-hoc test), compared to 
untreated slices (see above; Figure 13), suggesting that Abeta(1-42) did not affect the AMPAR-
mediated synaptic transmission. On the other hand, Abeta(1-42) induced a massively elevated 
firing (n=7; 0.5 h: 182.6±30.91%; 1 h: 242.29±83.31%, p=0.043; 1.5 h: 233.29±83.31%; 2 h: 
240.32±85.0%, p=0.036 and 2.5 h: 244.72±64.21%, p=0.001,  Mann-Whitney U-test; Figure 14) 
compared to untreated slices, suggesting that NMDARs are involved in the effect of Abeta(1-42).  
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Figure 13. Neither Abeta(1-42) nor ifenprodil changed fEPSPs amplitudes. Representative fEPSPs are 
shown before (b) and after (a) treatment in the upper panel, and panel A shows the changes of fEPSPs 
amplitudes over time. Neither Abeta(1-42) nor ifenprodil affected fEPSPs amplitudes (one-way repeated 
measures ANOVA with Bonferroni correction) (A). Bar graphs depict the mean of the last 5 min of every 
recording epoch. The level of fEPSPs amplitudes (the last 10 peak-to-peak amplitudes) were compared to 
the average 20 peak-to-peak amplitudes of the control level (0 h) in all cases. Error bars represent SEM. 
Abbreviations: Abeta(1-42) (amyloid-beta(1-42)), ifenprodil (α-(4-Hydroxyphenyl)-β-methyl-4-benzyl-1-
piperidineethanol (+)-tartrate) and fEPSPs (field excitatory postsynaptic potential). 
Several recent findings suggest that the deleterious effect of Abeta is mediated via the NR2B 
subunit-containing NMDARs (Tackenberg, Grinschgl et al. 2013, Zhang, Wang et al. 2013). To 
test whether the observed hyperexcitation in our experimental setup is sensitive to NR2B 
antagonism, we have applied ifenprodil, an antagonist of the NR2B. Ifenprodil did not change 
either fEPSPs (ifenprodil: n=5; 0.5 h: 102.26±1.35%; 1 h: 104.95±3.00%; 1.5 h: 105.45±3.91%; 
2 h: 103.28±4.53% and 2.5 h: 96.99±4.15%, one-way repeated measures ANOVA, Bonferroni 
post-hoc test; Figure 13) compared to the untreated slices, or spiking activity (ifenprodil: n=5; 
0.5 h: 127.11±53.62%, 1 h: 163.58±101.77%; 1.5 h: 81.37±37.37%, 2 h: 110.35±65.81% and 2.5 
h: 120.26±64.58%, Mann-Whitney U-test; Figure 14), suggesting that NR2B-activation is not 
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required for basic synaptic transmission in the CA1. However, Abeta(1-42) induced elevated 
spiking activity was prevented by ifenprodil (ifenprodil+Abeta(1-42): n=5; 0.5 h: 
157.44±84.19%; 1 h: 196.87±79.61%; 1.5 h: 116.36±61.71%; 2 h: 101.72±76.26% and 2.5 h: 
88.88±59.67%, p=0.038, Mann-Whitney U-test; Figure 14) without changing of fEPSPs 
amplitudes (ifenprodil+Abeta(1-42): n=5; 0.5 h: 100.17±1.53%; 1 h: 100.57±2.38%; 1.5 h: 
98.85±3.66%; 2 h: 95.45±4.97% and 2.5 h: 93.15±5.47%, one-way repeated measures ANOVA, 
Bonferroni post-hoc test; Figure 13).  
These results suggest that the hyperexcitability caused by Abeta(1-42) requires the activation 
of NR2B-subunit containing NMDARs, but not AMPARs. 
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Figure 14. Abeta(1-42) causes hyperexcitation via NR2B. Upper panel shows exemplar units from the 
respective recordings. Abeta(1-42) induced elevated spiking activity (untreated vs. Abeta(1-42): 1 h: 
*p=0.043; 2 h: *p=0.036 and 2.5 h: ***p=0.001; Mann-Whitney U-test). Ifenprodil did not affect 
spontaneous activity, but prevented the increased spiking rate caused by Abeta(1-42) (Abeta(1-42) vs. 
ifenprodil+Abeta(1-42) 2.5 h 
#
p=0.038; Mann-Whitney U-test). Error bars represent SEM; *p≤0.05; 
***p≤0.001 and #p≤0.05. Abbreviations: Abeta(1-42) (amyloid-beta(1-42)) and ifenprodil (α-(4-
Hydroxyphenyl)-β-methyl-4-benzyl-1-piperidineethanol (+)-tartrate). 
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6.4. AMYLOID-BETA(1-42) INDUCED IMPAIRMENT OF LTP  
REQUIRES NR2B ACTIVATION 
There is growing evidence that oligomer Abeta impairs synaptic plasticity in AD. Despite 
intense research, the exact mechanisms involved in Abeta-mediated synaptic dysfunction are not 
fully clear, thus we investigated the effect of Abeta(1-42) preparation on LTP in the hippocampal 
slices.  
Untreated slices showed a persistent elevated level of fEPSPs after LTP induction 
(168.33±5.58%, n=12), while Abeta(1-42) reduced the magnitude of LTP (124.35±4.88%, n=9; 
p<0.001, one-way ANOVA, Bonferroni post-hoc test; Figure 15).  
Several studies suggest that different NR2 subunits of NMDARs may have divergent roles in 
NMDAR-dependent LTP activation and Abeta pathology (reviewed by Koffie, Hyman et al. 
2011). To test whether LTP activation requires NR2B-containing NMDARs function, slices were 
treated with an NR2B antagonist, ifenprodil. We have observed that ifenprodil did not alter the 
level of LTP compared to untreated slices (176.81±4.93%, n=5; one-way ANOVA, Bonferroni 
post-hoc test), suggesting that NR2B-activation is not required for LTP in the CA1. Furthermore, 
ifenprodil prevents the Abeta(1-42) induced reduction of LTP magnitude (166.03±12.38%, n=5; 
p=0.003, one-way ANOVA, Bonferroni post-hoc test; Figure 15), suggesting that Abeta(1-42) 
induces LTP damage via NR2B-containing NMDARs.  
Based on these findings, we propose that NR2B-containing NMDARs activity is not required 
for LTP, but is essential for the effect of Abeta(1-42). 
 
 
 
 
 
Figure 15. Ifenprodil prevents Abeta(1-42)-induced LTP impairment. Upper panel shows 
representative fEPSPs before (b) and after (a) treatment. Panel A shows the changes of fEPSPs 
amplitudes over time. LTP was altered in Abeta(1-42) treated slices compared to untreated group 
(untreated vs. Abeta(1-42): ***p<0.001;  one-way ANOVA, Bonferroni post-hoc test) (B). Ifenprodil did 
not affect the level of LTP, however it prevented Abeta(1-42)-impaired LTP (Abeta(1-42) vs. 
ifenprodil+Abeta(1-42): 
##
p=0.003; one-way ANOVA, Bonferroni post-hoc test). Error bars represent 
SEM; ***p≤0.001 vs. untreated; ##p≤0.01; ###p≤0.001 vs. Abeta(1-42). Abbreviations: Abeta(1-42)  
(amyloid-beta(1-42)), LTP (long-term potentiation), fEPSPs (field excitatory postsynaptic potential) and 
ifenprodil (α-(4-Hydroxyphenyl)-β-methyl-4-benzyl-1-piperidineethanol (+)-tartrate). 
6.5. GLUTAMATE SCAVENGER RESCUES  
AMYLOID-BETA(1-42)-IMPAIRED LTP 
Li S et al., suggest a novel mechanism by which Abeta(1-42) oligomers induce synaptic 
impairment. The authors have shown that the peptide blocks the Glu uptake regulatory system 
which can lead to synapse depression (Li, Hong et al. 2009). To investigate this possibility, slices 
were treated with GPT and its substrate, Pyr for 10 min followed by Abeta(1-42) for 60 min, 
then LTP was induced.  
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We have found that Pyr+GPT treatment did not change the magnitude of LTP compared to 
untreated slices (Pyr+GPT: 157.32±6.68%, n=5; one-way ANOVA, Bonferroni post-hoc test, 
Figure 16). However, Abeta(1-42)-induced LTP damage was prevented by Glu scavenger 
(Abeta(1-42) vs. Pyr+GPT+Abeta(1-42): 159.66±6.37%, n=5; p=0.006; one-way ANOVA, 
Bonferroni post-hoc test; Figure 16).  
Our data suggest that applying Glu scavenger restores the Abeta(1-42)-induced reduction of 
LTP. 
 
Figure 16. Glu scavenger rescues Abeta(1-42)-impaired LTP. Insets show representative fEPSPs 
before (b) and after (a) treatment. Panel A represents the changes of fEPSPs amplitudes over time. 
Pyr+GPT treatment did not change the LTP level compared to untreated slices, however Abeta(1-42)-
induced LTP damage was prevented by Glu scavenger (Abeta(1-42) vs. Pyr+GPT+Abeta(1-42): 
##
p=0.006; one-way ANOVA, Bonferroni post-hoc test) (B). Error bars represent SEM; ***p≤0.001 vs. 
untreated; 
##
p≤0.01 vs. Abeta(1-42). Abbreviations: Abeta(1-42) (amyloid-beta(1-42)), LTP (long-term 
potentiation), fEPSPs (field excitatory postsynaptic potential), Pyr (sodium pyruvate) and GPT (glutamic-
pyruvic transaminase). 
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6.6. THE EFFECT OF AMYLOID-BETA(1-42) IS MIMICKED BY TBOA,  
A GLUTAMATE REUPTAKE INHIBITOR 
Based on previous findings, we supposed that Abeta may interrupt Glu uptake. In order to 
address, whether a Glu reuptake inhibitor, TBOA can mimick the effect of Abeta(1-42), we 
applied the slices with TBOA for 60 min before LTP induction. Indeed, LTP was impaired by 
TBOA compared to untreated slice (123.22±3.48%, n=6; p<0.001; one-way ANOVA, 
Bonferroni post-hoc test, Figure 17).  
 
Figure 17. Blocking NR2B restores TBOA-induced LTP impairment. Upper panel shows exemplar 
fEPSPs before (b) and after (a) treatment. Panel A represents the changes of fEPSPs amplitudes over 
time. LTP was impaired by TBOA compared to untreated group (untreated vs. TBOA: ***p<0.001; one-
way ANOVA, Bonferroni post-hoc test), which was prevented by ifenprodil (TBOA vs. 
ifenprodil+TBOA: 
##
p=0.013; one-way ANOVA, Bonferroni post-hoc test) (B). Error bars show SEM; 
***p≤0.001 vs. untreated; ##p≤0.01 and ###p≤0.001 vs. TBOA. Abbreviations: ifenprodil  
(α-(4-Hydroxyphenyl)-β-methyl-4-benzyl-1-piperidineethanol(+)-tartrate), TBOA (DL-threo-β-
benzyloxyaspartate), LTP (long-term potentiation) and fEPSPs (field excitatory postsynaptic potential). 
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Next, we tested whether NR2B subunit activation is required for the effect of TBOA. We 
have found that ifenprodil prevents TBOA-induced LTP damage, which suggests that NR2B 
subunit activation is essential for the effect of TBOA on LTP (TBOA vs. ifenprodil+TBOA: 
159.29±10.67%, n=4; p=0.013; one-way ANOVA, Bonferroni post-hoc test, see above, Figure 
17).  
We proceeded to apply Glu scavenger to test whether the inhibitory effect of TBOA was due 
to the elevated extracellular Glu level. To investigate this possibility, slices were treated with 
GPT and its substrate, Pyr for 10 min followed by TBOA for 60 min, then LTP was induced. We 
have found that TBOA failed to impair LTP after Glu scavenger treatment (TBOA vs. 
Pyr+GPT+TBOA: 169.28±8.18, n=5; p=0.001; one-way ANOVA, Bonferroni post-hoc test, 
Figure 18).  
Collectively these results suggest that TBOA and Abeta(1-42) share common pathway in 
synaptotoxicity. The effect of Abeta(1-42) is mimicked by Glu reuptake inhibition, however both 
could be prevented by a Glu scavenger and NR2B inhibition, suggesting that Abeta(1-42) 
disrupts synaptic plasticity by altering Glu recycling at the synapse in the CA1. 
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Figure 18. Glu scavenger restores the effect of TBOA. Insets show representative fEPSPs before (b) 
and after (a) treatment. Panel A represents the changes of fEPSPs amplitudes over time. TBOA impaired 
LTP, which was rescued by Glu scavenger (TBOA vs. Pyr+GPT+TBOA: 
###
p=0.001; Bonferroni post-
hoc test). Error bars represent SEM; ***p≤0.001 vs. untreated; ##p≤0.01 and ###p≤0.001 vs. TBOA. 
Abbreviations: TBOA (DL-threo-β-benzyloxyaspartate), LTP (long-term potentiation), fEPSPs (field 
excitatory postsynaptic potential), Pyr (sodium pyruvate) and GPT (glutamic-pyruvic transaminase). 
6.7. CHARACTERIZATION OF AMYLOID-BETA 
The size distribution of Abeta(1-42) oligomers formed in 50 μM after incubation at 37°C 
was studied on WB by using two different antibodies: the monoclonal BAM10 antibody is 
sequence specific and binds to the N-terminal end of the peptide, while OC stains the oligomers 
of fibrillar nature (protofibrils, oligomers with beta-sheet structure (Glabe 2008).  
Supplementary Fig. 3 shows the results of the WB experiments (Supplementary Figure 3). 
BAM10 staining reveals the presence of both low- and high- molecular weight oligomers in the 
sample, while their positive staining with the OC antibody indicates that they have protofibrillar 
characteristics. The presence of SDS stable dimers and trimers in the sample closely resembles to 
Abeta(1-42) derived from biological sources, namely from transfected 7PA2 cells (Davis, 
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Marsden et al. 2011) and from human brain (Shankar, Bloodgood et al. 2007, Klyubin, Betts et 
al. 2008). These species were shown to have strong synaptotoxic properties (Townsend, Shankar 
et al. 2006). On the other hand, protofibrillar species, which are also abundant in our sample, 
were also reported to be synaptotoxic (Minkeviciene, Rheims et al. 2009).  
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VII. DISCUSSION 
Neuronal hyperexcitability in early AD and in AD modeling mice is an emerging finding that 
points to a network dysfunction as a critical component of the pathomechanism. Soluble Abeta 
species have been increasingly implicated as the key pathologic components of the disease, thus 
elucidating the mechanisms by which these species alter neuronal function is important. There is 
growing evidence that soluble Abeta oligomers mediate synaptic impairment in AD, but the 
exact mechanism of synaptotoxicity remains to be determined. 
In my thesis work, we examined a possible pathway of neuronal excitability and impaired 
synaptic plasticity caused by Abeta. First, we identified two possible mechanisms that regulate 
extracellular excitatory events in the CA1, and then we examined how Abeta affects these 
events. Second, we investigated the receptors and receptor subunits that are required for Abeta-
induced excitotoxicity and LTP impairment. Third, we tested whether interfering with the 
pathway we identified previously can prevent the effect of Abeta peptide. 
7.1. THE UNDERLYING MECHANISM OF EVOKED FIELD POTENTIAL AND 
SPONTANEOUS SPIKING GENERATION ARE NOT CORRELATED 
Extracellular recordings of fEPSP is one of the most common ways for determining the 
excitation and synaptic plasticity in hippocampal slices. Evoked fEPSPs are commonly evoked 
by electric stimulation at Schaffer-collaterals and are recorded from the proximal apical dendrites 
of the CA1 stratum radiatum. Monitoring the changes in the peak-to-peak amplitudes of fEPSPs 
is widely used as a readout for investigation of synaptic plasticity. The changes of spontaneous 
spiking activity under conditions that modify network excitability are, however, less well studied 
in acute slices. In these sets of experiments we have studied the involvement of AMPARs and 
NMDARs in fEPSPs evoked by Schaffer-stimulation and in spontaneous firing in the CA1.  
We shown that these two electrophysiological markers previously thought to underlie 
measures of excitation, are not correlated. Under our conditions, inhibiting AMPAR with CNQX 
blocked fEPSPs, however, the spiking rate remained unaffected. In contrast, modulating 
NMDAR function influenced spontaneous activity without any change in evoked fEPSPs. 
Blocking NMDARs ablated, while enhancing NMDAR function increased spontaneous activity.  
Importantly, the spontaneous spikes we recorded here were almost exclusively localized to 
the stratum pyramidale layer of CA1; hence they were presumably generated by principal cells. 
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Multi-unit activity recordings do not allow to separate the firing from individual neurons and 
may include bursts of spikes fired by the same neuron. Thus in our study, spiking represents the 
global amount of activity within this network, and most probably the activity of principal cells. 
The firing rates observed in this study were comparable to previously reported values in slices of 
CA1 of the guinea pig (0.22 and 1.8 spikes/sec) (Cohen and Miles 2000).  
7.2. POSSIBLE INVOLVEMENT OF THE CA1 LOCAL MICROCIRCUITRY IN 
THE REGULATION OF SPONTANEOUS SPIKING 
The activity of CA1 pyramidal cells is regulated by the excitation arriving from CA3 through 
the Schaffer-collateral, and by the inhibition of the local interneuron microcircuitry. Although 
the activity of CA1 inhibitory cells has been reported to be scarce compared to CA3 in acute 
slices, powerful pyramidal somatic inhibition could be detected upon minimal electric 
stimulation (Beyeler, Retailleau et al. 2013), showing that the inhibition is very effective.  
What is the driving force of the interneuronal activity? One possible explanation is that the 
spontaneous activity of the incoming axons of the CA3 principal cells recruits a CA1 inhibitory 
microcircuitry via the Schaffer-collateral. This is unlikely, because there is no correlation 
between CA3 multi-unit activity and the extracellularly recorded inhibitory post-synaptic 
potential in the CA1 (Beyeler, Retailleau et al. 2013). Another possibility is that the spontaneous 
discharge of CA1 interneurons, although scarce, is keeping a strong blockade of the principal 
cells. Favoring this hypothesis, the resting membrane potential is more hyperpolarized in CA1 
compared to CA3 pyramidal neurons (Fricker, Verheugen et al. 1999, Tyzio, Ivanov et al. 2003). 
These spontaneous discharges might be regulated by the ambient Glu concentration via 
NMDARs. Indeed, tonic activation of NMDARs by ambient Glu has been described in virtually 
all pyramidal cells of the CA1 of the hippocampus in slice models (Sah, Hestrin et al. 1989, 
Dalby and Mody 2003, Angulo, Kozlov et al. 2004, Cavelier, Hamann et al. 2005). Importantly, 
as Le Meur et al. has shown (Le Meur, Galante et al. 2007), neither AMPA/kainate receptors nor 
mGluRs contributes to this tonic excitation of pyramidal neurons. This tonic current is not 
dependent on vesicular release of transmitters from neurons, but is affected by inhibition of the 
enzyme converting Glu in glutamine in glial cells, indicating that ambient Glu is mainly of glial 
origin. Consistent with these findings, we have also shown that spontaneous spiking is driven by 
NMDAR activity, but not by AMPARs, indicating that the tonic activation could reach the 
threshold of spike generation.  
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The question arises that why do not AMPARs mediate spontaneous activity? NMDARs have 
a much higher affinity for Glu than do AMPARs; in steady-state conditions, the EC50 for Glu at 
NMDARs is over two orders of magnitude lower than at AMPARs (Patneau and Mayer 1990). 
Esyn NMDARs containing the NR2B subunit have even higher affinity than synaptic NR2A-
containing receptors (Priestley, Laughton et al. 1995). It should be noted, that evoked firing, 
which is usually detected in the form of population spikes (pop-spikes for short) in CA1 
extracellular recordings, is mediated by AMPAR signaling (Wood and Tattersall 2001). Under 
our conditions, action potentials were not inhibited by AMPAR blockade (CNQX). The reason 
behind this discrepancy might be that evoked pop-spikes require a synchronous discharge of a 
population of cells. This coordinated function might be based on the fast AMPAR function. 
7.3. AMYLOID-BETA(1-42)-INDUCED HYPEREXCITATION AND  
LTP IMPAIRMENT REQUIRES NR2B ACTIVATION 
Numerous studies have reported that Abeta can affect the function of NMDARs (Shankar, 
Bloodgood et al. 2007, Juhasz, Marki et al. 2009, Dinamarca, Rios et al. 2012, Tackenberg, 
Grinschgl et al. 2013, Xu, Cao et al. 2014), which may lead to excitotoxicity and neuronal 
hyperactivation seen in the early stage of AD. Abeta can bind to integrin receptors and this 
complex initiates a molecular cascade mediated by Fyn kinase, which subsequently 
phosphorylates NMDARs (Larson, Sherman et al. 2012). Furthermore, there is evidence that 
Abeta affects esyn NMDAR function. Memantine, a clinically effective drug in the treatment of 
AD, was shown to block preferentially esyn NMDARs, further arguing for the Abeta and esyn 
NMDARs connection (Szegedi, Juhasz et al. 2010, Xia, Chen et al. 2010). 
Next, we investigated the effect of Abeta(1-42) on spontaneous firing, and found that the 
peptide increased the rate of spontaneous discharges, but did not alter evoked fEPSPs. These 
results suggest that NMDARs are involved in the hyperexcitability induced by Abeta(1-42). 
Similar results have been recently reported by Varghese et al. using cultured embryonic rat 
hippocampal cells. Abeta increased spontaneous firing activity dose-dependently, reaching the 
maximum after 1 hour of treatment, which was followed by a complete cessation of spikes 
following a few hours (Varghese, Molnar et al. 2010). The discrepancy between this and our 
result may be due to the fact that the authors have used a cell culture largely devoid of glial 
elements, while we have used a complex microcircuitry built up from all of the neuronal cell 
types (including glia) forming elaborate connections.  
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Abeta induced enhancement of spontaneous spiking activity could be prevented by blocking 
the NR2B subunits, suggesting that Abeta activates esyn NMDARs. The role of esyn or 
perisynaptic NMDARs in Abeta(1-42)-induced changes in functional synaptic plasticity and 
subsequent cell death has been received much attention recently (Palop and Mucke 2009, Li, Jin 
et al. 2011, Talantova, Sanz-Blasco et al. 2013). Esyn NMDARs contain predominantly NR2B 
subunits, which in contrast to NR2A-containing synaptic NMDARs trigger apoptotic signaling 
cascade (Hardingham, Fukunaga et al. 2002). Recently, it was shown using organotypic 
hippocampal cell cultures, that Abeta induces neuronal death and subsequent tau 
hyperphosporylation via esyn NR2B subunit (Tackenberg, Grinschgl et al. 2013).  
Blocking NR2B subunits does not only prevent hyperexcitation caused by Abeta, but also 
rescues Abeta induced LTP impairment, suggesting that blocking NR2B subunits might be a 
promising target in AD. Tackenberg et al. also suggest that esyn NR2B-enriched NMDARs 
activation is essential for tau-dependent neurodegeneration (Tackenberg, Grinschgl et al. 2013). 
It was also shown that the opposite form of synaptic plasticity, LTD requires both syn and esyn 
receptor activation (Liu, Yang et al. 2013), while LTP is not mediated by esyn NMDARs (Hu, 
Klyubin et al. 2009, Zhang, Wang et al. 2013). It should be noted, however, that contradictory 
data is available on the role of NR2B-subunit containing NMDARs on LTP: esyn NDMARs are 
also recruited to the synapse during LTP (Harney, Jane et al. 2008) and may play an essential 
role in LTP maintenance (Foster, McLaughlin et al. 2010, Hasegawa, Mukai et al. 2014). 
However, others have reported that Abeta oligomers directly activate NMDARs especially via 
NR2A subunit (Domingues, Almeida et al. 2007, Texido, Martin-Satue et al. 2011). In our 
hands, ifenprodil is not required the LTP magnitude suggesting that NR2B activation do not 
require for LTP.  
7.4. GLUTAMATE SCAVENGER AS A NOVEL THERAPEUTIC OPPORTUNITY 
AGAINST ALZHEIMER’S DISEASE 
Since the late 1980’s, disturbances in the  Glu uptake system has been suggested as a cause 
for AD which leads to excitatoxicity in the hippocampal and the cortical regions (Hardy, 
Cowburn et al. 1987, Perry, Perry et al. 1987). The spillover of Glu from the synapse contributes 
to normal physiological processes in the hippocampus (Asztely, Erdemli et al. 1997, Min, 
Rusakov et al. 1998, Scimemi, Fine et al. 2004). However, under certain pathological conditions, 
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increased spillover results in excessive esyn receptor activation, which enhances network 
excitability and promotes pro-apoptotic pathways. 
Abeta has been shown to elevate extracellular Glu concentration in the brain without altering 
gamma-aminobutyric acid (GABA) level (Mura, Zappettini et al. 2012). The mechanism behind 
this is probably the inhibition of the transporters mediating Glu clearance (Figure 19A). The 
level of brain extracellular Glu is regulated by EAATs expressed mainly on the astrocytes, which 
efficiently remove the excess of this neurotransmitter from the synaptic cleft (reviewed by 
(Anderson and Swanson 2000), thus Glu transporters play a critical role in limiting esyn 
diffusion of Glu and provide normal function of glutamatergic neurons (Hertz and Zielke 2004). 
Indeed, Abeta was shown to inhibit both glial and neuronal EAATs (Bashir, Alford et al. 1991, 
Masliah, Alford et al. 2000, Li, Hong et al. 2009, Marosi, Fuzik et al. 2009). Rossi and 
coworkers have reported that under certain pathological conditions, for example during epileptic 
activity, ischaemia or AD, EAAT may reverse its function leading to Glu release into the 
extracellular side (Rossi, Oshima et al. 2000). Furthermore, down-regulation or abnormal 
expression and protein levels of EAAT1 and EAAT2 are altered in the hippocampus and frontal 
cortex of AD patients (Scott, Pow et al. 2002, Jacob, Koutsilieri et al. 2007) and in APP 
transgenic mice (Masliah, Alford et al. 2000), further supporting that Glu level regulation fails 
during AD pathomechanism. These effects may lead to Glu spillover from the synapses and 
subsequent activation of esyn receptors, however the exact mechanism by which Abeta impairs 
EAATs remains unknown. Some available data suggest an indirect mechanism, namely Abeta 
interaction with the cell membrane or after being endocytosed, the peptide can trigger 
intracellular signaling pathways in astrocytes (Wyss-Coray, Loike et al. 2003), which may 
modulate Glu transporters levels/activity by alternating the phosphorylation states of EAATs 
(Daniels and Vickroy 1999, Gosselin, Meylan et al. 2013). Moreover, Abeta induced 
hyperexcitability appears to involve tau, because deletion of tau reduces seizures in some of the 
transgenic mouse models of AD (Roberson, Scearce-Levie et al. 2007). Li S et al. suggest that 
Abeta depresses peak NMDAR currents as a result of desensitization of the receptor (Li, Shankar 
et al. 2010). Interesting result is that several Glu uptake inhibitors are able to reduce NMDAR 
desensitization (Arnth-Jensen, Jabaudon et al. 2002).  
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Figure 19. Abeta(1-42) perturbs Glu recycling at synapses. Abeta enhances the ambient Glu level by 
the blockade of Glu transporters (EAATs). Elevated ambient Glu level would be a spillover and 
subsequent esyn NR2B-enriched esyn NMDAR activation. Excessive activation of NMDARs increases 
the influx of Ca
2+
 and activates signaling pathways responsible for tau hyperphosphorylation (GSK3β), 
inhibited LTP (p38-MAPK), enhanced LTD, apoptosis and finally cell death (A). Decreasing extracellular 
Glu level using Glu scavenger may be able to prevent the synaptic plasticity impairment caused by Abeta 
(B). Abbreviations: Abeta(1-42) (amyloid-beta(1-42)), Glu (glutamate), EAATs (excitatory amino-acid 
glutamate transporters), esyn (extrasynaptic), NMDAR (N-methyl-D-aspartate receptor), GSK3β 
(glycogen synthase kinase 3β), LTP (long-term potentiation), LTD (long-term depression), pTau 
(hyperphosporylated tau protein), pCREB (phosporylated cyclic adenosine monophosphate response 
element binding protein) and p38-MAPK (p38-mitogen-activated protein kinase).  
Our results extend this line of research by showing that reducing Glu that has been spilled-
over from the synapse, with a Glu scavenger enzyme also prevents Abeta-induced LTP 
impairment (Figure 19B). We have also shown that the effect of Abeta(1-42) is mimicked by 
TBOA, a Glu reuptake inhibitor. Blocking NR2B-subunit or using a Glu scavenger restores 
impaired LTP caused by either of the compounds. These results agree with Li and his coworkers’ 
findings: reducing ambient Glu in the brain is protective against Abeta induced synaptic 
depression (LTD) (Li, Hong et al. 2009). A recent paper by Chen and Herrup makes the 
suggestion that although the level of glutamine synthase is elevated in AD brains, its activity is 
severely compromised by oxidative damage, leading to impaired Glu metabolism (Chen and 
Herrup 2012). It is also reported that the interaction between Abeta and glutamine synthase can 
 53 / 71 
 
induce the inactivation of the enzyme leading to excessive depolarization of the neurons via 
mGluRs and NMDARs (Blanchard, Stockwell et al. 2002, Blanchard, Thomas et al. 2002).  
Neuronal hyperactivity and the appearance of seizures could further aggravate memory loss 
through a synergic mechanism. The secretion of Abeta is governed by neuronal activity 
(Kamenetz, Tomita et al. 2003, Cirrito, Kang et al. 2008) during pathological events, such as 
epileptiform activity induced by electrical stimulation, as well as during normal physiological 
processes, such as the sleep-wake cycle (Kang, Lim et al. 2009). Increased excitability induced 
by Abeta may result in a “vicious cycle” leading to massive neuronal loss and the formation of 
Abeta deposits. Excessive Glu release activates NMDARs which in turn stimulate a shift from α- 
to β-secretase cleavage of the APP facilitating further Abeta(1-42) production (Lesne, Ali et al. 
2005). 
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VIII. SUMMARY 
Taken together, we have shown that two electrophysiological events recorded from 
hippocampal slices, evoked fEPSPs and spontaneous spikes are not generated by the same 
mechanisms (Varga, Juhasz et al. 2014). Evoked fEPSPs, but not firing activity was mainly 
regulated by AMPARs. In contrast, spontaneous spikes are mediated by NMDAR function. Bath 
application of synaptotoxic Abeta(1-42)-enhanced firing activity in an NR2B-dependent manner 
without altering evoked fEPSPs. These effects may contribute to synaptic dysfunctions seen in 
early AD.   
Our results also provide evidence that Abeta(1-42) impairs Glu recycling at the synapse, 
which leads to Glu spillover and NR2B-subunit containing NMDAR activation (Varga, Juhasz et 
al. 2014). Excessive activation of NMDARs increases Ca
2+
 influx and activates signaling 
pathway responsible for synaptic loss, apoptosis and neuronal death. Blocking NR2B or 
decreasing extracellular Glu level offers protection against the synaptic plasticity impairment 
caused by Abeta.  
Based on our results, we suggest a possible therapeutic targets against Abeta. Glu scavengers 
may be a novel therapeutic opportunities for AD, because reducing ambient Glu in the brain may 
be protective against Abeta-induced synaptic dysfunction. Abeta and Glu toxicity mediated 
dysfunction have been closely associated, however decreasing the extracellular Glu level can be 
also protective in other conditions such as brain ischemia (Marosi, Fuzik et al. 2009), stroke 
(Campos, Rodriguez-Yanez et al. 2011), traumatic brain injury (Boyko, Stepensky et al. 2012) or 
certain psychiatric disorders (Mitani, Shirayama et al. 2006, Shinohe, Hashimoto et al. 2006).  
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IX. CONCLUSION 
The main conclusions of my thesis are: 
1) Evoked fEPSPs, but not spontaneous firing is mainly regulated by AMPARs. In 
contrast, spontaneous spikes are mediated by NMDAR function. 
2) Abeta(1-42)-induced hyperexcitation and LTP impairment requires NR2B-subunit 
containing NMDARs activation. 
3) Abeta(1-42) perturbs Glu recycling that is prevented by a Glu scavenger. 
4) Blocking Glu reuptake mimics the effects of Abeta. 
5) Glu scavenger may be novel therapeutic opportunity for AD. 
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XII. SUPPLEMENTARY MATERIAL 
 
 
Supplementary Figure 1. Panel A represents the changes of fEPSPs amplitudes over time: CNQX 
abolished evoked fEPSPs even under condition that promotes NMDAR activation (in Low Mg
2+
 ACSF) 
(A). Upper panel shows representative fEPSPs before (gray) and after (black) treatment. Bar graphs show 
the average of the fEPSPs amplitudes of the 25-30 min period after treatment (B). Error bars show SEM; 
***p<0.001. Abbreviations: fEPSPs (field excitatory postsynaptic potential), CNQX (6-cyano-7-
nitroquinoxaline-2,3-dione), NMDAR (N-methyl-D-aspartate receptor) and Low Mg
2+
 ACSF (low 
Mg2SO4-containing artificial cerebrospinal fluid). 
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Supplementary Figure 2. Low concentration of AMPA (0.05 µM) increased basal activity which 
hindered the effective detection of spikes. Figure shows representative traces before (left) and after (right) 
AMPA application. Abbreviation: AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid). 
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Supplementary Figure 3. Abeta(1-42) samples used for the recordings contained clearly detectable SDS-
stable trimers (≈15 kDa) and higher molecular weight protofibrils. Staining with OC antibody, which is 
specific for species having beta-sheet conformation, shows that the small low-n oligomers are of 
prefibrillar nature. Abbreviation: Abeta(1-42) (amyloid-beta(1-42)). 
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Abstract. Alzheimer’s disease (AD) is the most prevalent form of neurodegenerative disorders characterized by neuritic plaques
containing amyloid- peptide (A) and neurofibrillary tangles. Evidence has been reported that A1-42 plays an essential
pathogenic role in decreased spine density, impairment of synaptic plasticity, and neuronal loss with disruption of memory-
related synapse function, all associated with AD. Experimentally, A1-42 oligomers perturb hippocampal long-term potentiation
(LTP), an electrophysiological correlate of learning and memory. A was also reported to perturb synaptic glutamate (Glu)-
recycling by inhibiting excitatory-amino-acid-transporters. Elevated level of extracellular Glu leads to activation of perisynaptic
receptors, including NR2B subunit containing NMDARs. These receptors were shown to induce impaired LTP and enhanced
long-term depression and proapoptotic pathways, all central features of AD. In the present study, we investigated the role of
Glu-recycling on A1-42-induced LTP deficit in the CA1. We found that A-induced LTP damage, which was mimicked by the
Glu-reuptake inhibitor TBOA, could be rescued by blocking the NR2B subunit of NMDA receptors. Furthermore, decreasing the
level of extracellular Glu using a Glu scavenger also restores TBOA or A induces LTP damage. Overall, these results suggest
that reducing ambient Glu in the brain can be protective against A-induced synaptic disruption.
Keywords: Alzheimer’s disease, glutamate scavenger, glutamate-reuptake, long-term potentiation, NR2B, TBOA
INTRODUCTION
Amyloid- (A), a misfolded peptide, is widely
regarded as a central player in the pathogenesis of
Alzheimer’s disease (AD). The accumulation of sol-
uble A [1] in the brain of patients and animal models
of AD is associated with impairments of cognition
and memory [2–4]. In addition, both the synthetic
and brain-derived soluble A have been shown to
damage certain forms of synaptic plasticity, corre-
lates of learning and memory [5, 6]. Despite intense
research, the mechanisms involved in A-mediated
neuronal degeneration and dysfunction are not well
understood.
∗Correspondence to: Viktor Szegedi, PhD., Biological Research
Center – Biochemistry, Temesvari krt. 32, Szeged H-6726, Hungary.
Tel.: +36 70 2418260; E-mail: szegedi.viktor@brc.mta.hu.
The hippocampus is especially affected in AD
including hippocampal-dependent cognitive abilities
such as learning and memory. Long-term potentiation
(LTP), a form of synaptic plasticity in the CA1 field
of the hippocampus, is impaired in animal models of
AD. Numerous studies reported that A1-42 oligomers
block hippocampal LTP ex vivo [7–9] and in vivo
[10, 11].
Although the increased neuronal excitability caused
by A seems to contribute to and to be a key part
of the pathomechanism of AD, the exact mechanisms
by which neuronal over-activity develops is unknown.
Glutamate (Glu) excitotoxicity has been established
to have a major role in AD pathogenesis; however,
how A induces its effects is poorly understood.
Numerous findings confirmed that excitotoxic effects
of Glu contribute to progressive neuronal loss in AD
[12–14]. Inhibited excitatory-amino-acid-transporters
ISSN 1387-2877/15/$35.00 © 2015 – IOS Press and the authors. All rights reserved
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(EAATs) may be a central player in this mechanism,
and indeed, recent findings suggest that A oligomers
perturb synaptic plasticity by altering Glu-recycling
at the synapse [15, 16], resulting in elevated ambi-
ent extracellular Glu-level in the brain [17, 18], which
might be responsible for the overexcitation seen in
AD. A blocks Glu-reuptake by inhibiting both neu-
ronal and glial Glu transporters [16, 19], which might
lead to extrasynaptic NMDAR (esyn NMDAR) acti-
vation. Esyn NMDAR activation causes inhibited LTP
[5], enhanced long-term depression (LTD) [20], and
apoptosis [21].
The aim of this study was to confirm that A causes
synaptic Glu-spillover and esyn NMDAR activation,
which leads to impaired synaptic plasticity in the
CA1. We show that blocking Glu-reuptake with TBOA
also impairs LTP, and both TBOA- and A-induced
synaptic damage could be rescued by blocking NR2B
subunit. Moreover, reducing the level of extracellu-
lar Glu by applying a glutamate-scavenger enzyme
GPT also provides protection against impaired synap-
tic plasticity by TBOA and A.
MATERIALS AND METHODS
Compounds
For the preparation of artificial cerebrospinal
fluid (ACSF), all salts, glucose, sodium pyruvate
(Pyr), glutamic-pyruvic transaminase (GPT),
DL-threo--benzyloxyaspartate (TBOA), and -(4-
Hydroxyphenyl)--methyl-4- benzyl-1-piperidinee-
thanol (+)-tartrate salt (ifenprodil) were purchased
from Sigma-Aldrich (St. Louis, MO). A1-42 was
synthetized at the Department of Medical Chemistry
University of Szeged, Hungary. Detailed description
of the synthesis and characterization of A1-42 is
reported in [7].
Animals
The study conformed to EU Directive 2010/63/EU
and was approved by the regional Station for Ani-
mal Health and Food Control under Project License
XVI/8/2013. BALB/c mice were housed in groups of
2-3 under standard conditions (24◦C, 12-h light-dark
cycle) with food and water available ad libitum.
Ex vivo electrophysiology
Hippocampal slices of 400m in thickness were
prepared from the brains of 3-month old mice using
a standard protocol [22]. Briefly, slices were incu-
bated in ACSF gassed with 95% O2, 5% CO2 at 35◦C
for 60 min. ACSF was composed of (in mM) 130
NaCl, 3.5 KCl, 3 CaCl2, 1.5 MgSO4, 0.96 NaH2PO4,
24 NaHCO3, and 10 D-glucose, pH 7.4. Individual
slices were transferred to a 3D-MEA chip with 60 tip-
shaped and 60m high electrodes spaced by 200m
(Qwane Biosciences, Lausanne, Switzerland). The sur-
rounding solution was quickly removed, and the slice
was immobilized by placing a grid onto it. The slice
was continuously perfused with oxygenated ACSF
(3 ml/min at 36◦C) throughout the entire recording
session. Unfiltered data were recorded using a stan-
dard, commercially available MEA 60 setup (Multi
Channel Systems MCS GmbH, Reutlingen, Germany).
Field excitatory postsynaptic potentials (fEPSPs) were
recorded from the proximal stratum radiatum at 5 kHz.
Stimulation protocol
The Schaffer-collateral was stimulated by injecting
a biphasic voltage waveform (–100/+100s) through
one selected electrode at 0.033 Hz. Care was taken to
place the stimulating electrode in the same region at
every slice. The peak-to-peak amplitudes of fEPSPs at
the proximal stratum radiatum of CA1 were analyzed.
After a 30-min incubation period, the threshold and
maximum stimulation intensities for evoked responses
were determined. To evoke responses, 30% of the max-
imal stimulation intensity was used. LTP was evoked
by theta-burst stimulation (TBS). TBS comprised of 15
bursts given at 5 Hz and individual burst contained 4
pulses given at 100 Hz per burst. The level of LTP was
compared to the average of the last 10 peak-to-peak
amplitudes of evoked fEPSPs before TBS.
Drug treatments
After 10-min control level, slices were treated with
1M A1-42 or 5M TBOA for 60-min before LTP
was induced. Other cohort of slices was treated with
3M ifenprodil or 0.82 mM Pyr for 10-min then 2.06
U/ml GPT for 60-min before LTP induction. Separate
groups of slices were treated with these compounds
together with A1-42 or TBOA.
Statistics
Statistical significance was determined by using
ANOVA on ranks test with the post hoc Dunn’s method
(SigmaPlot 11 software package). The p value ≤0.05
was considered significant in all cases.
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RESULTS
Aβ1-42-impaired LTP requires NR2B activation
We recorded fEPSPs from the stratum radiatum of
the CA1 using MEA electrodes. The peak-to-peak
amplitudes of fEPSPs were analyzed from the proximal
part of stratum radiatum.
First, we verified the effect of A1-42 preparation
on LTP in the hippocampal slices. Untreated slices
showed a persistent elevated level of fEPSPs after
LTP induction (168.33 ± 5.58%, n = 12), while A1-42
reduced the magnitude of LTP (124.35 ± 4.88%, n = 9,
p < 0.05, nonparametric ANOVA, Dunn post-hoc test;
Fig. 1). Several recent studies suggested that differ-
ent NR2 subunits of NMDARs may have divergent
roles in NMDAR-dependent LTP activation and A
pathology (see discussion). To test whether LTP acti-
vation requires NR2B-containing NMDARs function,
slices were treated with an NR2B antagonist, ifen-
prodil. We observed that ifenprodil did not alter the
level of LTP compared to control (176.81 ± 4.93%,
n = 5), suggesting that NR2B-activation is not required
for LTP in the CA1. Furthermore, ifenprodil prevents
the A1-42 effect on LTP (166.03 ± 12.38%, n = 5,
p < 0.05, ANOVA on ranks, Dunn post-hoc test; Fig. 1),
suggesting A1-42 induce LTP damage is via NR2B-
containing NMDARs. None of the applied compounds
altered the amplitude of fEPSPs during the wash-in
period.
Glu-scavenger rescues the Aβ1-42-impaired LTP
To determine whether A1-42 affects Glu-reuptake,
we used an enzymatic Glu-scavenger system to
reduce extracellular Glu-levels. Slices were treated
Fig. 1. Blocking NR2B subunit prevents A1-42-induced LTP damage. Insets show representative fEPSPs before (black) and after treatment.
LTP was altered in A1-42 treated slices compared to untreated group (untreated versus A1-42: ∗p < 0.05; ANOVA on ranks, Dunn post-hoc
test). Ifenprodil did not change the level of LTP, however, it rescued the A1-42-impaired LTP. Error bars represent SEM; #p < 0.05 versus
A1-42.
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Fig. 2. Glu-scavenger restores A1-42-induced LTP damage. Insets show representative fEPSPs before (black) and after treatment. Pyr+GPT
treatment did not affect the level of LTP compared to untreated slices, however A1-42 induced LTP impairment was prevented by Glu-
scavenger (A1-42 versus Pyr+GPT+A1-42: #p < 0.05; ANOVA on ranks, Dunn post-hoc test). Error bars represent SEM; ∗p < 0.05 versus
untreated; #p < 0.05 versus A1-42.
with GPT and its substrate, Pyr for 10 min fol-
lowed by A1-42 for 60 min, then LTP was induced.
We have found that Pyr+GPT treatment does not
affect the level of LTP compared to control slices
(157.32 ± 6.68%, n = 5; Fig. 2). However, A1-42-
induced LTP damage was prevented by Glu-scavenger
(Pyr+GPT+A1-42: 159.66 ± 6.37%, n = 5 versus
A1-42, p < 0.05, ANOVA on ranks, Dunn post-hoc
test; Fig. 2).
The effect of Aβ1-42 is mimicked by TBOA, a
Glu-reuptake inhibitor
TBOA was applied for 60 min before LTP induction.
LTP was impaired by TBOA compared to untreated
slice (123.22 ± 3.48%, n = 6, p < 0.05; ANOVA on
ranks, Dunn post-hoc test, Fig. 3). Next, we tested
whether NR2B subunit activation is required for
the effect of TBOA. We have found that ifenprodil
prevents TBOA-induced LTP damage suggesting
NR2B subunit activation is essential for the effect of
TBOA on LTP (ifenprodil+TBOA: 159.29 ± 10.67%,
n = 4 versus TBOA: p < 0.05; ANOVA on ranks, Dunn
post-hoc test, Fig. 3). We proceeded to apply Glu-
scavenger to test whether the inhibitory effect of TBOA
was due to the elevated extracellular Glu-level. Indeed,
TBOA-failed to impair LTP after Glu-scavenger treat-
ment (Pyr+GPT+TBOA: 169.28 ± 8.18, n = 5 versus
TBOA, p < 0.05; ANOVA on ranks, Dunn post-hoc
test, Fig. 4). Collectively these results suggest that
TBOA and A share common pathway in synaptotoxi-
city. The effect of A1-42 is mimicked by Glu-reuptake
inhibition; however both could be prevented by a Glu-
scavenger and NR2B inhibition suggesting that A1-42
disrupts synaptic plasticity by altering Glu-recycling
at the synapse in the CA1. Again, none of the applied
compounds altered fEPSP amplitude during the wash-
in period.
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Fig. 3. Ifenprodil prevents TBOA-impaired LTP. Insets show representative fEPSPs before (black) and after treatment. LTP was impaired by
TBOA compared to untreated group (untreated versus TBOA: ∗p < 0.05; ANOVA on ranks, Dunn post-hoc test), however TBOA-induced LTP
impairment was restored by ifenprodil (TBOA versus ifenprodil+TBOA: #p < 0.05; ANOVA on ranks, Dunn post-hoc test). Error bars represent
SEM; ∗p < 0.05 versus untreated; #p < 0.05 versus TBOA.
DISCUSSION
There is growing evidence that soluble A
oligomers mediate synaptic impairment in AD, but
the exact mechanism of synaptotoxicity remains to be
determined. Numerous studies have reported that A
can affect the function of NMDARs [23–27], which
may lead to excitotoxicity and neuronal hyperactiva-
tion seen in the early stage of AD. Recent findings
suggest that A binds to prion protein, metabotropic
Glu receptor 5, and integrin receptors, and this com-
plex initiates a molecular cascade mediated by fyn
kinase [28–30], which subsequently phosphorylates
NMDARs.
An additional pathway of A-mediated hyperex-
citation could be, however, that the concentration
of extracellular Glu is increased by A. We have
shown previously, that the excitatory effect of A, as
was determined by the rate of spontaneous spiking
in hippocampal slices, is mediated by extrasynap-
tic NMDARs [22]. In the present study, we show
that A causes Glu spillover and subsequent esyn
NMDAR activation, which could be prevented by
either NR2B blockade or by “mopping-up” Glu with a
Glu-scavenger enzyme.
TBOA mimics the effects of Aβ
A has been shown to elevate extracellular Glu
concentration in the brain without altering gamma-
aminobutyric acid (GABA) level [18]. The mechanism
behind this is probably the inhibition of the trans-
porters mediating Glu-clearance. The level of brain
extracellular Glu is regulated by EAATs expressed
mainly on the astrocytes, which efficiently remove
the excess of this neurotransmitter from the synaptic
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Fig. 4. Glu-scavenger prevents TBOA-induced LTP damage. Insets show representative fEPSPs before (black) and after treatment. TBOA-
induced LTP impairment was restored by Glu-scavenger (TBOA versus Pyr+GPT+TBOA: #p < 0.05; ANOVA on ranks, Dunn post-hoc test).
Error bars represent SEM; ∗p < 0.05 versus untreated; #p < 0.05 versus TBOA.
cleft (reviewed by [31]). Indeed, A was shown to
inhibit both glial and neuronal EAATs [16, 17, 32].
Moreover, Noda and coworkers have reported that
A may even cause reverse functioning of EAAT,
leading to Glu-release from glial cells [33]. Further-
more, down-regulation or abnormal expression and
protein levels of EAAT1 and EAAT2 are altered in
the hippocampus and frontal cortex of AD patients
[34, 35] and in amyloid- protein precursor transgenic
mice [32], further supporting that Glu-level regula-
tion fails during AD pathomechanism. These effects
may lead to Glu-spillover from the synapses and sub-
sequent activation of esyn receptors. Of particular
interest here, esyn NMDARs containing mainly NR2B
subunit were shown to activate apoptotic pathways
and promote synaptic depression [21]. In contrast,
NR2A subunit-containing NMDARs localized mainly
at the synaptic domain are antiapoptotic and participate
in the induction of LTP in the CA1. We previ-
ously reported that A1-42 induces hyperexcitability
via NR2B-containing NMDARs [22]. Indeed, block-
ing selectively NR2B subunits protected against A
effects (including LTP impairment), suggesting that
NR2B could be a promising target against AD [5,
8, 9, 36, 37]. Tackenberg et al. also suggest that
esyn NR2B-containing NMDARs activation is essen-
tial for tau-dependent neurodegeneration [26]. It was
also shown that the opposite form of synaptic plastic-
ity, LTD requires both syn and esyn receptor activation
[20], while LTP is not mediated by esyn NMDARs [8,
9]. It should be noted, however, that contradictory data
is available on the role of NR2B NMDARs on LTP:
esyn NDMARs are also recruited to the synapse dur-
ing LTP [38] and may play an essential role in LTP
maintenance [39, 40].
Our results extend this line of research by showing
that reducing Glu that has been spilled-over from the
synapse with a Glu-scavenger enzyme also prevents
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A induced LTP impairment. Moreover, we show that
blocking EAATs by a selective inhibitor, TBOA, mim-
ics the effects of A: both compounds impair LTP, and
this could be prevented by ifenprodil or GPT (Glu-
scavenger).
Reducing ambient Glu in the brain is protec-
tive against A induced LTD enhancement [16]. A
recent paper by Chen and Herrup makes the sugges-
tion that although the level of glutamine-synthase is
elevated in AD brains, its activity is severely com-
promised by oxidative damage, leading to impaired
Glu-metabolism [41].
A and Glu-toxicity mediated dysfunction has been
closely associated; however, decreasing the extracellu-
lar Glu-level can be protective in other conditions such
as brain ischemia [42], stroke [43], traumatic brain
injury [44] or certain psychiatric disorders [45, 46].
CONCLUSIONS
Collectively, our results provide evidence that A
impair Glu-recycling at the synapse, which leads to
Glu-spillover and NR2B activation. Blocking NR2B or
decreasing extracellular Glu offers protection against
the synaptic plasticity impairment caused by A.
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Neuronal hyperexcitability is a phenomenon associated with early Alzheimer’s disease.The underlying mechanism is considered to
involve excessive activation of glutamate receptors; however, the exact molecular pathway remains to be determined. Extracellular
recording from the CA1 of hippocampal slices is a long-standing standard for a range of studies both in basic research and in
neuropharmacology. Evoked field potentials (fEPSPs) are regarded as the input, while spiking rate is regarded as the output of
the neuronal network; however, the relationship between these two phenomena is not fully clear. We investigated the relationship
between spontaneous spiking and evoked fEPSPs using mouse hippocampal slices. Blocking AMPA receptors (AMPARs) with
CNQX abolished fEPSPs, but left firing rate unchanged. NMDA receptor (NMDAR) blockade with MK801 decreased neuronal
spiking dose dependently without altering fEPSPs. Activating NMDARs by small concentration of NMDA induced a trend of
increased firing. These results suggest that fEPSPs are mediated by synaptic activation of AMPARs, while spontaneous firing is
regulated by the activation of extrasynaptic NMDARs. Synaptotoxic Abeta(1-42) increased firing activity withoutmodifying evoked
fEPSPs. This hyperexcitation was prevented by ifenprodil, an antagonist of the NR2B NMDARs. Overall, these results suggest that
Abeta(1-42) induced neuronal overactivity is not dependent on AMPARs but requires NR2B.
1. Introduction
Extracellular recording from hippocampal slices has long
been a method of choice for determining the changes in
excitability and synaptic plasticity of the CA1 microcircuitry
[1]. Spontaneous spikes and, far more often, field excitatory
postsynaptic potentials (fEPSPs) are recorded extracellularly
from a local network of neurons; however, the relationship
between these two phenomena is not fully clear. Intuitively,
both electrophysiological events correlate with the excitabil-
ity of the network under investigation, but these events are
generated by different mechanisms. Field EPSPs are mainly
composed of subthreshold events from a population of neu-
rons, like dendritic depolarizations [2] and glial contributions
to the net extracellular charge-flow, arising mainly from the
function of transporters [3, 4]. In contrast, spontaneous firing
represents only neuronal suprathreshold events [5]. Another
difference is that a fEPSP is evoked by a stimulus, and
therefore it is the result of a coordinated and synchronized
electrical activity of a cell population, mediated by synaptic
connections. Spontaneous spikes, in contrast, are not evoked
by an external stimulus, and they are more likely to be
dependent on intrinsic network connections and properties
[6].
N-Methyl-D-aspartate receptor (NMDAR) and 𝛼-Ami-
no-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPAR) play a key role in generating rapid excitatory events
in the CA1, but these receptors serve different purposes.Their
relative contribution to fEPSPs is well described [7]; however,
their involvement in spontaneous spike-generation remains
unknown and data on the correlation of extracellularly
recorded field responses and action potentials are scarce.
Activation of glutamate (Glu) receptors is known to play
an important role in the mechanisms of neuronal plasticity
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that might be the cellular basis of learning and memory
[8]. Several studies have shown that the synaptic plasticity is
impaired in Alzheimer’s disease (AD) [9], the most common
form of neurodegenerative disease, characterized by the pres-
ence of insoluble amyloid deposits in the brain. Overwhelm-
ing evidence suggests that the main component of plaques,
amyloid-beta (Abeta) peptide, is thought to be responsible
for the synaptic and cellular pathology of AD (for review
see [10]). Numerous studies have reported that the severity
of AD strongly correlates with decreased synapse density in
hippocampus and cortex and with disruption of memory-
related synapse function. Literature data strongly support
the synaptotoxicity of Abeta(1-42), and the accumulation of
soluble Abeta(1-42) [11] in the brain of patients and animal
models of AD is associated with impairments of cognition
and memory [12–14]. Recently, Abeta(1-42) was shown to
induce epileptiform activity, both in vitro [15] and in vivo,
and transgenic mice overexpressing Abeta develop seizures
over time [16]. Moreover, AD patients have an estimated
87 times higher probability of developing epileptic seizures
compared to age-matched population [17]. Despite the recent
advancement in the research of the pathomechanisms of
AD, the exact mechanism by which neuronal overactivity
develops is unknown.
Recent findings suggest that Abeta blocks neuronal gluta-
mate (Glu) uptake at synapses, leading to increased Glu level
at the synaptic cleft [18]. Increased brain extracellularGlu, but
not 𝛾-aminobutyric acid (GABA), concentration was found
upon Abeta administration by use of microdialysis technique
[19, 20]. A resultant rise in Glu levels would lead to a spillover
and activation of extra- or perisynapticNMDARs enriched in
the B isoform of the NMDAR 2 subunit (NR2B), which play
a major role in the induction of long-term depression (LTD)
[21] and have also been shown to help mediate the inhibition
of long-term potentiation (LTP) by soluble Abeta oligomers
[22].
In this study we investigated the mechanisms by which
fEPSPs and spontaneous firing are regulated in the CA1 of
hippocampal slices.We confirmed that fEPSP, but not spiking
activity, is mainly mediated by AMPARs. In contrast, spon-
taneous activity is regulated by NMDARs. Bath application
of synaptotoxic Abeta(1-42) greatly enhanced spontaneous
firing rate, which could be prevented by blocking NR2B
subunits.
2. Experimental Procedures
2.1. Compounds. For the preparation of artificial cere-bro-
spinal fluid (ACSF), all salts, glucose, 6-cyano-7-nitroquin-
oxaline-2,3-dione (CNQX), (+)-MK-801 hydrogen male-
ate, and 𝛼-(4-Hydroxyphenyl)-𝛽-methyl-4-benzyl-1-piperi-
dineethanol (+)-tartrate salt (ifenprodil) were purchased
from Sigma-Aldrich (St. Louis, MO).
2.2. Animals. The study conformed to EU Directive
2010/63/EU and was approved by the regional Station for
Animal Health and Food Control under Project License
XVI/8/2013. BALB/c mice were housed in groups of 2-3
under standard conditions (24∘C, 12 h light-dark cycle) with
food and water available ad libitum.
2.3. Ex Vivo Electrophysiology. Hippocampal slices of 400 𝜇m
in thickness were prepared from the brains of 3-month-
old mice using a standard protocol [23]. Briefly, slices were
incubated in artificial cerebrospinal fluid ACSF gassed with
95%O
2
and 5%CO
2
at 35∘C for 60min. ACSF was composed
of (in mM) 130 NaCl, 3.5 KCl, 3 CaCl
2
, 1.5 MgSO
4
, 0.96
NaH
2
PO
4
, 24 NaHCO
3
, and 10 D-glucose, pH 7.4. Individual
slices were transferred to a 3D-MEA chip with 60 tip-shaped
and 60𝜇m high electrodes spaced by 200𝜇m (Qwane Bio-
sciences, Lausanne, Switzerland). The surrounding solution
was quickly removed, and the slice was immobilized by
placing a grid onto it. The slice was continuously perfused
with oxygenated ACSF (3mL/min at 36∘C) throughout the
entire recording session. Unfiltered data were recorded using
a standard, commercially available MEA 60 setup (Multi
Channel Systems MCS GmbH, Reutlingen, Germany). Field
EPSPs were recorded from the proximal stratum radiatum
at 5 kHz, while spontaneous spiking activity was recorded
from the CA1 stratum pyramidale at a frequency of 25 kHz
for 5min epochs. For analyzing and sorting the spiking activ-
ity, Spike2 software package (Cambridge Electronic Design,
Cambridge, UK) was used. Recordings were filtered between
300 and 3000Hz offline, and the threshold for spike detection
was 2.5 fold higher than the noise level. The data of those
electrodes were included in the analysis where the initial
spiking activity was above 0.5Hz. Firing activity ranged from
150 to 1000 spikes/5min. Data are considered as multiunit
activity.
2.3.1. Stimulation Protocol. TheSchaffer-collateral was stimu-
lated by injecting a biphasic voltage waveform (−100/+100 𝜇s)
through one selected electrode at 0.033Hz. Care was taken to
place the stimulating electrode in the same region at every
slice. The peak-to-peak amplitudes of fEPSPs at the proximal
stratum radiatum of CA1 were analyzed. After a 30min
incubation period, the threshold and maximum stimulation
intensities for evoked responses were determined. To evoke
responses, 30% of the maximal stimulation intensity was
used. The level of LTP (the last 10 peak-to-peak amplitudes)
was compared to the average of the last 20 peak-to-peak
amplitudes of evoked fEPSPs before applying theta-burst
stimulation (TBS). TBS comprised of 15 bursts given at 5Hz
and individual burst contained 4 pulses given at 100Hz per
burst.
2.3.2. Drug Treatments. All slices were incubated for 30min
without stimulation in the recording chamber before any
recording was done. Following the first spike-recording,
slices were left to incubate a further 60min with contin-
uous fEPSP recording and then slices were treated with
10 𝜇M CNQX or 10 𝜇M MK801 or 25 𝜇M MK801 or ACSF
containing low concentration of Mg
2
SO
4
(low Mg2+ ACSF;
0.25mM) or 0.5 𝜇M NMDA or 0.05 𝜇M AMPA for 30min
(see Figure 1(c)). Spontaneous activity was recorded before
and 30min after treatment for 5min and the spiking data
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Figure 1: Exemplar recordings and the timeline of the experiments. Both evoked fEPSPs and spiking activity recording electrodes were
located in the CA1 region of mouse hippocampal slice.The fEPSPs were recorded from the stratum radiatum (a) and the spontaneous spiking
was recorded from the stratum pyramidale (b). Both fEPSPs and spiking activity were recorded from the same slice. Data were considered as
multiunit activity. (c) shows the timeline of the recordings. The initial spiking activity (recorded at 0 h) was considered as 100% in each slice.
was compared to the untreated group recorded at the same
time point. Other cohorts of slices were treated with 1𝜇M
oligomer Abeta(1-42), ifenprodil (3 𝜇M), and ifenprodil +
Abeta(1-42) for 2.5 h. The spiking activity was recorded at
every 30min for 5min. The effect of CNQX was also tested
in lowMg
2
SO
4
-containingACSF (0.25mM), wheremodified
ACSF was perfused to the slices from the beginning of
the experiment. Electric stimulation was stopped during
spontaneous activity recordings. Spiking frequency of each
slice (number of spikes) was normalized to the initial firing
activity (following the first 30min incubation; 0 h), which
was taken as 100% in all channels. Following this, slices were
treated with 1 𝜇M oligomer Abeta(1-42) for 60min and then
LTP was induced by the TBS protocol. LTP was followed
for 90min after TBS. During treatment, evoked fEPSPs were
recorded.
2.4. Synthesis and Characterization of Abeta(1-42). Detailed
description of the synthesis and characterization of Abeta(1-
42) is reported in [23, 24]. Briefly, a depsipeptide derivative
of Abeta(1-42) was synthesized and, after purification, it
was used in lyophilized form. A 200𝜇M stock solution
of the peptide was prepared in 0.1mM NaOH, and the
pH was set to 11.0. After incubation for 2 h at ambient
temperature, the stock solution was diluted into ACSF to
a concentration of 50𝜇M and the pH was set to 7.3. The
peptide solution was incubated for 12 h at 37∘C and, prior
to use, it was diluted with ACSF to a final concentration
of 1 𝜇M. Aggregation grade and the size distribution of the
oligomers were checked by Western blots by following the
methods described in [23]. Oligomers were detected either
with sequence-specific BAM10 antibody (Sigma-Aldrich) or
with conformation specific OC antibody (Millipore), which
detects the oligomers of fibrillar nature, that is, with beta sheet
structure.
2.5. Statistics
2.5.1. Statistical Analysis for fEPSPs. Testing for normal-
ity was done with the Kolmogorov-Smirnov normality
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Figure 2: AMPA receptorsmediate fEPSPs but not spontaneous activity. BlockingAMPARs abolished fEPSPs (a). Bar graphs show the average
of the fEPSPs amplitudes of the 25–30min period after treatment. CNQX induced a complete reduction of evoked fEPSPs (𝑛 = 5, 𝑃 < 0.001)
(b); however the spiking activity was not affected (c). Inset at the right panel shows representative fEPSPs before (grey) and after (black)
treatment and representative spike trains. Error bars show SEM; ∗∗∗𝑃 ≤ 0.001.
test. Our data have shown normal distribution; hence,
independent-samples 𝑡-test and one-way repeated measures
analysis of variance (ANOVA) were used with the Bonferroni
test for post hoc analysis. The 𝑃 value ≤ 0.05 was considered
significant in all cases. Data were analyzed using SPSS
statistical software.
2.5.2. Statistical Analysis for Spiking Rate. Kolmogorov-
Smirnov test was used also for testing normality of these
data. Since our data have shown nonparametric distribution,
we used nonparametric tests (Kruskal-Wallis test was fol-
lowed by Mann-Whitney 𝑈 test) for determining differences
between two and several groups. Data were analyzed using
SPSS. 𝑃 value of ≤ 0.05 was considered significant in all cases.
3. Results
3.1. Field EPSPs, but Not Spontaneous Spikes, Are Mediated by
AMPARs. We recorded fEPSPs from the stratum radiatum
(Figure 1(a)) and in parallel spontaneous spikes from the
stratum pyramidale (Figure 1(b)) of the CA1. Both fEPSPs
and spontaneous activity could be abolished by application
of 1 𝜇M tetrodotoxin (data not shown).
First, we investigated the contribution of AMPARs to
evoked fEPSPs and spontaneous activity, using CNQX, an
AMPAR inhibitor. Blocking AMPARs resulted in a complete
reduction of evoked fEPSPs (untreated: 𝑛 = 5; 98.84 ± 2.41%
versus CNQX: 𝑛 = 5; 4.62 ± 0.45%, 𝑃 = 0.001, inde-
pendent samples 𝑡-test; Figures 2(a) and 2(b)). Conversely,
spiking activity remained unchanged (untreated: 𝑛 = 5;
139.55 ± 44.95% versus CNQX: 𝑛 = 5; 182.18 ± 56.76%,
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Figure 3: NMDA receptors mediate spontaneous activity but not fEPSPs. Blocking (MK801) or enhancing (low-Mg2+ ACSF) NMDAR
function did not influence fEPSPs (a). Right panel shows representative fEPSPs before (grey) and after (black) treatment. Bar graphs show
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Mann-Whitney𝑈 test; Figure 2(c)), suggesting that AMPARs
play a key role in generating fEPSPs but not spontaneous
spiking. Under physiological conditions, NMDARs activa-
tion is dependent on depolarization, for example, on previous
AMPARs activation. Thus we changed to low Mg2+ ACSF
(0.25mM) to remove the depolarization-dependent Mg2+
plug from the NMDAR. Applying 10 𝜇MCNQX to lowMg2+
ACSF slices for 30min, fEPSPs were completely blocked
(control: 𝑛 = 6; 95.54 ± 81% versus CNQX in low Mg2+-
containingACSF: 𝑛 = 6; 6.44±0.36%,𝑃 < 0.001, independent
samples 𝑡-test; see Supplementary Figure 1 available online at
http://dx.doi.org/10.1155/2014/584314). We have also tried to
activate AMPARs by applying a low concentration of AMPA
(0.05𝜇M), but we observed epileptiform field responses
and a huge increase of basal activity which hindered the
unambiguous detection of action potentials (Supplementary
Figure 2).
3.2. Spontaneous Firing, but Not fEPSP, Is Governed by
NMDARFunction. Next, we focused onNMDARs. Applying
an NMDAR antagonist, MK801 resulted in a dose-dependent
decrease of spiking rate (untreated: 𝑛 = 5; 139.55 ± 44.95%
versus MK801 in 10 𝜇M: 𝑛 = 5; 96.73%±32.22, 𝑃 = 0.48;
MK801 in 25 𝜇M: 𝑛 = 5; 29.23 ± 22.93, 𝑃 = 0.031, Mann-
Whitney 𝑈 test; Figure 3(c)). MK801 did not have any effect
on fEPSP in either 10 𝜇M or 25 𝜇M (untreated: 𝑛 = 5;
98.8 ± 2.4% versus MK801 in 10 𝜇M: 𝑛 = 5; 101.23 ± 1.17%
versus MK801 in 25 𝜇M: 𝑛 = 5, 104.49 ± 1.72%; one-way
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Figure 4: Abeta(1-42) impairs LTP. Representative fEPSPs from both control and Abeta(1-42) groups. Field EPSP was recorded before (grey)
and 90min after LTP induction (control is in black and Abeta(1-42) is in red) from the proximal stratum radiatum of CA1 (see above).
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ANOVA and Bonferroni post hoc test; Figures 3(a) and 3(b)).
Another cohort of slices was treated with ACSF having
reduced Mg2+ concentration for 30min. We have observed
a massively elevated frequency of the spontaneous spiking
activity compared to the untreated slices (𝑛 = 7, 316.34 ±
41.89%, 𝑃 = 0.004, Mann-Whitney 𝑈 test; Figure 3(c)), but
evoked fEPSP responses remained unaltered (𝑛 = 7, 101.54 ±
1.69%, one-way ANOVA and Bonferroni post hoc test). Based
on these results we hypothesized that spontaneous firing
is mediated by the ambient Glu concentration acting on
the extrasynaptic NMDARs. Therefore we tried to activate
selectively this set of receptors by applying low concentration
of NMDA (0.5 𝜇M) in normal ACSF [25]. This treatment
resulted in unchanged fEPSPs (untreated: 𝑛 = 5; 98.8 ± 2.4%
versus NMDA: 𝑛 = 9; 94.03 ± 1.04%; independent-samples
𝑡-test) but induced a trend of elevated firing rate (untreated:
𝑛 = 5; 139.55±44.95%versus NMDA: 𝑛 = 9; 253.02±105.9%,
𝑃 = 0.51, Mann-Whitney 𝑈 test; Supplementary Figure 3).
3.3. Abeta(1-42) Impairs LTP. A major drawback of Abeta
studies is that the activity of various Abeta preparations
may vary between protocols and even between batches. We
verified the activity of Abeta batches we have used for this
study by determining their effect on CA1 LTP. Abeta(1-42)
was applied for 60min before inducing LTP by using TBS.
Untreated slices showed a robust and permanent elevation
of evoked fEPSPs after TBS (𝑛 = 7; 155.48 ± 7.16% 90min
after TBS), while slices having received Abeta(1-42) failed to
exhibit permanent LTP (𝑛 = 8; 122.54 ± 4.75% 90min after
TBS,𝑃 = 0.002, independent-samples 𝑡-test; Figures 4(a) and
4(b)).
3.4. Abeta(1-42) Induces Hyperexcitation via NR2B. Firing
rate was determined every 30min in 5min epochs within
the time frame of the recordings. In the untreated slices the
amplitude of fEPSPs increased slightly until 1.5 h reaching
103.36 ± 2.67% of the initial amplitude and then decreased
to initial value (𝑛 = 5; 0.5 h: 100.8±1.65%; 1 h: 102.9±1.84%;
2 h: 100.86±3.38%; and 2.5 h: 98.18±4.04%, one-way repeated
measures ANOVA and Bonferroni post hoc test; Figures 5(a)
and 5(b)). Similarly, spiking frequency did not change over
time (𝑛 = 5; 0.5 h: 124.34±29.72%; 1 h: 129.57±53.28%; 1.5 h:
139.55±44.95%; 2 h: 102.48±28.42; and 2.5 h: 76.16±28.08%,
Mann-Whitney 𝑈 test; Figure 6).
Abeta(1-42) applied in 1 𝜇M did not change fEPSPs
amplitudes (Abeta(1-42): 𝑛 = 7; 0.5 h: 107.08 ± 2.43%; 1 h:
106.41 ± 2.93%; 1.5 h: 103.54 ± 3.07%; 2 h: 100.92 ± 3.06%;
and 2.5 h: 97.1 ± 2.97% compared to untreated slices, see
above; Figure 5), suggesting that Abeta(1-42) did not affect
the AMPAR-mediated synaptic transmission. On the other
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hand, Abeta(1-42) induced a massively elevated firing (𝑛 =
7; 0.5 h: 182.6 ± 30.91%; 1 h: 242.29 ± 83.31%, 𝑃 = 0.043;
1.5 h: 233.29 ± 83.31%; 2 h: 240.32 ± 85.0%, 𝑃 = 0.036;
and 2.5 h: 244.72 ± 64.21%, 𝑃 = 0.001, Mann-Whitney 𝑈
test; Figure 6) compared to untreated slices, suggesting that
NMDARs are involved in the effect of Abeta(1-42). Several
recent reports suggested that the deleterious effect of Abeta
is mediated via the NR2B subunit-containing NMDARs (see
Section 4). To test whether the observed hyperexcitation in
our experimental setup is sensitive to NR2B antagonism, we
have applied ifenprodil (3 𝜇M), an antagonist of the NR2B.
Ifenprodil did not alter either fEPSPs (ifenprodil: 𝑛 = 5; 0.5 h:
102.26±1.35%; 1 h: 104.95±3.00%; 1.5 h: 105.45±3.91%; 2 h:
103.28±4.53%; and 2.5 h: 96.99±4.15% compared to control,
see above; Figure 5) or spiking activity (𝑛 = 5; ifenprodil:
0.5 h: 127.11 ± 53.62%, 1 h: 163.58 ± 101.77%; 1.5 h: 81.37 ±
37.37%, 2 h: 110.35 ± 65.81%; and 2.5 h: 120.26 ± 64.58%;
Figure 6), suggesting that NR2B-activation is not required for
basic synaptic transmission in the CA1. However, Abeta(1-42)
induced elevated spiking activity was prevented by ifenprodil
(ifenprodil + Abeta(1-42): 𝑛 = 5; 0.5 h: 157.44 ± 84.19%; 1 h:
196.87± 79.61%; 1.5 h: 116.36± 61.71%; 2 h: 101.72± 76.26%;
and 2.5 h: 88.88 ± 59.67%, 𝑃 = 0.048, Mann-Whitney 𝑈 test
compared toAbeta(1-42), see above; Figure 6)without chang-
ing of fEPSPs amplitudes (ifenprodil + Abeta(1-42): 𝑛 = 5;
0.5 h: 100.17 ± 1.53%; 1 h: 100.57 ± 2.38%; 1.5 h: 98.85 ±
3.66%; 2 h: 95.45 ± 4.97%; and 2.5 h: 93.15 ± 5.47%; Figure 5),
suggesting that the hyperexcitability caused by Abeta(1-42)
requires the activation of extrasynaptic NR2B receptors, but
not AMPARs.
3.5. Characterization of Abeta(1-42). The size distribution of
Abeta(1-42) oligomers formed in 50 𝜇M after incubation at
37∘C was studied on Western blots by using two different
antibodies; the monoclonal BAM10 antibody is sequence
specific and binds to the N-terminal end of the peptide,
while OC stains the oligomers of fibrillar nature (protofibrils,
oligomerswith beta sheet structure) [26]. Supplementary Fig-
ure 4 shows the results of theWB experiments. BAM10 stain-
ing reveals the presence of both low- and high-molecular-
weight oligomers in the sample, while their positive staining
with the OC antibody indicates that they have protofibrillar
characteristics.Thepresence of SDS stable dimers and trimers
in the sample closely resembles Abeta(1-42) derived from
biological sources, namely, from transfected 7PA2 cells [27]
and from human brain [28, 29]. These species were shown to
have strong synaptotoxic properties [30]. On the other hand,
protofibrillar species, which are also abundant in our sample,
were also reported to be synaptotoxic [16].
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4. Discussion
4.1. AMPA Receptors Regulate fEPSPs and NMDA Receptors
Mediate Spontaneous Spiking. Extracellular fEPSP recordings
are the gold standard for determining the excitation and
synaptic plasticity in hippocampal slices. The changes of
spontaneous spiking activity under conditions that modify
network excitability are, however, less well studied in acute
slices. In these sets of experiments we have studied the
involvement of AMPARs and NMDARs in fEPSPs evoked
by Schaffer-stimulation and in spontaneous firing in the
CA1. We show that these two electrophysiological markers,
previously thought to underlie measures of excitation, are
not correlated. Importantly, the spikes we recorded here
were almost exclusively localized to the pyramidal layer
of CA1; hence, they were presumably from principal cells.
Multiunit activity recordings do not allow separating the
firing from individual neurons and may include bursts
of spikes fired by the same neuron. Thus, in our study,
spiking represents the global amount of activity within this
network and most probably the activity of principal cells.
The firing rates observed in this study were comparable to
previously reported values in slices of CA1 of the guinea pig
(0.22 and 1.8 spikes/sec) [6]. Under our conditions, blocking
AMPAR with CNQX inhibited fEPSPs, however, the spiking
activity did not change. In contrast, modulating NMDAR
function affected spontaneous firing without any change in
evoked fEPSPs. Blocking NMDARs ablated, while enhancing
NMDAR function increased spontaneous activity.
4.2. Possible Involvement of the CA1 Local Microcircuitry in
the Regulation of Spontaneous Spiking. Direct comparison
of data from CA3 spiking regulation and our CA1 data is
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difficult, because glutamatergic pyramidal cells of the CA3
form massive recurrent loops, a feature that is missing in
the CA1. Therefore, the activity of CA1 pyramidal cells
is regulated by the excitation arriving from CA3 through
the Schaffer-collateral and by the inhibition of the local
interneuron microcircuitry. Although the activity of CA1
inhibitory cells has been reported to be scarce, compared to
CA3 in acute slices, powerful pyramidal somatic inhibition
could be detected upon minimal electric stimulation [31],
showing that the inhibition is very effective. What is the
driving force of the interneuronal activity? One possible
explanation is that the spontaneous activity of the incoming
axons of the CA3 principal cells recruits a CA1 inhibitory
microcircuitry via the Schaffer-collateral. This is unlikely,
because there is no correlation between CA3 multiunit
activity and the extracellularly recorded inhibitory postsy-
naptic potential in the CA1 [31]. Another possibility is that
the spontaneous discharge of CA1 interneurons, although
scarce, is keeping a strong blockade of the principal cells.
Favoring this hypothesis, the resting membrane potential is
more hyperpolarized in CA1 compared to CA3 pyramidal
neurons [32, 33]. These spontaneous discharges might be
regulated by the ambient Glu concentration via NMDARs.
Indeed, tonic activation of NMDARs by ambient glutamate
has been described in virtually all pyramidal cells of the CA1
of the hippocampus in slice models [34–37]. Importantly,
as Le Meur et al. have shown [38], neither AMPA/kainate
receptors normetabotropic glutamate receptors contribute to
this tonic excitation of pyramidal neurons.This tonic current
is not dependent on vesicular release of transmitters from
neurons but is affected by inhibition of the enzyme converting
Glu, in glutamine in glial cells, indicating that ambient Glu
is mainly of glial origin. Consistent with these findings,
we have also shown that spontaneous spiking is driven by
NMDAR activity, but not by AMPARs, indicating that the
tonic activation could reach the threshold of spike generation.
The question arises as follows: why do not AMPARs mediate
spontaneous activity? NMDARs have a much higher affinity
for Glu than AMPARs do; in steady-state conditions, the
EC50 for Glu at NMDARs is over two orders of magnitude
lower than that at AMPARs [39]. Extrasynaptic NMDARs
containing the NR2B subunit have even higher affinity than
synaptic NR2A-containing receptors [40]. It should be noted
that evoked firing, which is usually detected in the form of
population spikes (pop-spikes for short) in CA1 extracellular
recordings, is mediated by AMPAR signaling [41]. Under our
conditions, action potentials were not inhibited by AMPAR
blockade. The reason behind this discrepancy might be that
evoked pop-spikes require a synchronous discharge of a
population of cells.This coordinated functionmight be based
on the fast AMPAR function.
4.3. Abeta(1-42) Impairs LTP and Hyperexcites without Alter-
ing fEPSPs in the CA1 . Neuronal hyperexcitability in early
AD and in AD modeling mice is an emerging finding that
points to a network dysfunction as a critical component
of the pathomechanism. Soluble Abeta species have been
increasingly implicated as the key pathologic components of
the disease, thus elucidating the mechanisms by which these
species alter neuronal function is important. We confirmed
that the Abeta(1-42) preparationwe use is really synaptotoxic,
impairing LTP. Next we tested its effect on spontaneous
firing and found that it enhanced the rate of spontaneous
discharges but did not alter evoked fEPSPs. These results
suggest that NMDARs are involved in the hyperexcitability
induced by Abeta(1-42). Similar results have been recently
reported by Varghese et al. using cultured embryonic rat hip-
pocampal cells. Abeta increased spontaneous firing activity
dose dependently, reaching the maximum after 1 hour of
treatment, which was followed by a complete cessation of
spikes following a few hours [42]. The discrepancy between
this and our result may be due to the fact that the authors
have used a cell culture largely devoid of glial elements, while
we have used a complex microcircuitry built up from all of
the neuronal cell types (including glia) forming elaborate
connections.
The forms of NMDAR are heterotetramer including two
NR1 and two NR2 subunits [43]. One particular subunit,
NR2B, is mainly localized in extrasynaptic side. Abeta
induced elevation of spiking activity could be prevented by
blocking the NR2B subunits, suggesting that Abeta acti-
vates extrasynaptic NMDARs. The role of extrasynaptic or
perisynaptic NMDARs in Abeta(1-42)-induced changes in
functional synaptic plasticity and subsequent cell death has
received much attention recently [22, 44, 45]. Extrasynaptic
NMDARs contain predominantly NR2B subunits, which
in contrast to NR2A-containing synaptic NMDARs trigger
apoptotic signaling cascade [46]. Recently it was shown, using
organotypic hippocampal cell cultures, that Abeta induces
neuronal death and subsequent tau hyperphosporilation via
extrasynaptic NR2B subunit [47]. Blocking NR2B subunits
not only prevents hyperexcitation caused by Abeta but also
rescues Abeta induced LTP impairment [22, 48], suggesting
that blocking NR2B subunits might be a promising target
in AD. However, others have reported that Abeta oligomers
directly activate NMDARs especially via NR2A subunit [49,
50].
5. Conclusions
Taken together, we show that two electrophysiological events,
recorded from hippocampal slices, which evoked fEPSPs
and spontaneous firing, are not mediated by the same
mechanisms. Evoked fEPSPs, but not firing activity, were
mainly regulated by AMPARs. In contrast, spontaneous
spikes are governed by NMDAR function. Bath applications
of synaptotoxic Abeta(1-42) enhanced firing activity in an
NR2B-dependent manner without altering evoked fEPSPs.
These effects may contribute to synaptic dysfunctions seen in
early AD.
6. Highlights
(i) Spontaneous discharges and evoked fEPSPs were
recorded from the CA1 of murine slices.
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(ii) AMPA receptor blockade ablates fEPSPs without any
effect on spiking rate.
(iii) NMDA receptor modulation affects spontaneous
spiking, but not evoked fEPSPs.
(iv) Synaptotoxic amyloid-beta leaves evoked fEPSPs
unaltered but increases firing activity via NR2B.
(v) These results confirm that amyloid-beta induces
hyperexcitation through NR2B activation.
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Abstract Hsp27 belongs to the small heat shock pro-
tein family, which are ATP-independent chaperones.
The most important function of Hsp27 is based on its
ability to bind non-native proteins and inhibit the ag-
gregation of incorrectly folded proteins maintaining
them in a refolding-competent state. Additionally, it
has anti-apoptotic and antioxidant activities. To study
the effect of Hsp27 on memory and synaptic functions,
amyloid-β (Aβ) accumulation, and neurodegeneration,
we generated transgenic mice overexpressing human Hsp27
protein and crossed with APPswe/PS1dE9 mouse strain, a
mouse model of Alzheimer's disease (AD). Using different
behavioral tests, we found that spatial learning was impaired
in ADmodel mice and was rescued by Hsp27 overexpression.
Electrophysiological recordings have revealed that excitabili-
ty of neurons was significantly increased, and long-term po-
tentiation (LTP) was impaired in AD model mice, whereas
they were normalized in Hsp27 overexpressing AD model
mice. Using anti-amyloid antibody, we counted significantly
less amyloid plaques in the brain of APPswe/PS1dE9/Hsp27
animals compared to AD model mice. These results suggest
that overexpression of Hsp27 protein might ameliorate certain
symptoms of AD.
Keywords Heat shock proteins . Transgenic mice . Mouse
model . Alzheimer's disease . Amyloid plaques . Behavior
tests . Electrophysiological recordings . Real-time Q-PCR
Introduction
AD is one of the most common neurodegenerative diseases,
and its prevalence is strongly correlated with aging (Evans
et al. 1989). AD is characterized by progressive loss of
memory and cognitive functions (McKhann et al. 1984).
The pathological hallmarks of AD are extracellular amyloid
plaque deposition, formation of intracellular neurofibrillary
tangles, and other alterations in the brain such as activation
of microglial cells, oxidation of lipids, induction of reactive
oxygen species, disruption of neuronal metabolic homeosta-
sis, and neuronal cell death (Serrano-Pozo et al. 2011; Monji
et al. 2001). Amyloid plaques and neurofibrillary tangles are
present mainly in brain regions involved in learning, mem-
ory, and emotional behaviors, primarily in the hippocampus
(Mattson 2004).
Heat shock proteins (Hsps) are ubiquitously expressed
evolutionary conserved proteins which are upregulated by
different stressors and also in various pathological condi-
tions. Most of the stress-induced proteins are molecular
chaperons, and they have an essential role in biosynthesis,
transport, translocation, folding, and assembly of other pro-
teins (Morimoto et al. 1992). Under stress, Hsps prevent
protein misfolding and oligomerization, and they transfer
misfolded proteins to the proteasome for degradation
(Becker and Craig 1994). They also assist in the mainte-
nance of normal cellular homeostasis and metabolism.
Hsp27 belongs to the small heat shock protein (sHsp)
family, which are ATP-independent chaperones (Jakob et al.
1993). The most important function of sHsps is that they can
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inhibit the aggregation of incorrectly folded proteins by
binding to non-native proteins, and maintain them in a
refolding-competent state (Haslbeck and Buchner 2002).
Moreover, they also have anti-apoptotic and antioxidant
activities and can bind to the actin cytoskeleton and stabilize
it (Arrigo et al. 2002, Preville et al. 1999, Wang and Spector
1996).
Hsps are upregulated in several neurodegenerative
diseases and can protect brain cells against free radical
injury, oxidative stress, and misfolded proteins (Kalmar
and Greensmith 2009). Several studies indicate that
chaperones are potent suppressors of neurodegeneration
and are, therefore, promising therapeutic targets for pro-
tein conformational disorders (reviewed inMuchowski and
Wacker 2005). For example, treating a polyglutamine disease
model with an antiulcer drug, geranylgeranylacetone (GGA),
which can induce the expression of different Hsps, could
suppress the accumulation of pathogenic proteins and amelio-
rate the related phenotype (Katsuno et al. 2005). In a rat model
of Parkinson's disease, Hsp104 was found to be similarly
efficient (Lo Bianco et al. 2008). An increased level of ex-
pression of small Hsps and Hsp70 in the brain of AD patients
has been reported in a number of studies (Perez et al. 1991;
Muchowski and Wacker 2005). Several studies suggest that
expression of Hsps could suppress the progression of AD
(Magrané et al. 2004; Muchowski and Wacker 2005; Evans
et al. 2006). Hoshino et al. (2011) investigated the effect of
overexpression of Hsp70 on AD-related phenotypes, using
double transgenic mice overexpressing Hsp70 and a mutant
(Swedish) type of APP (APPswe). They demonstrated that
overexpression of Hsp70 inhibited the development of the
pathological phenotype of AD and the resultant cognitive
deficit, possibly through its effects on antiaggregation,
neuroprotection, and stimulation of Aβ clearance.
To study the effect of a small heat shock protein,
Hsp27, on memory and synaptic functions, Aβ accumu-
lation, and neurodegeneration, we generated transgenic mice
overexpressing the human Hsp27 protein and crossed them with
the APPswe/PS1dE9 mouse strain, a widely used mouse model
of AD.
Materials and methods
Animals
The study conformed to EU Directive 2010/63/EU and
was approved by the regional Station for Animal Health
and Food Control (Csongrád, Hungary) under project
license XVI/02752/2009. Mice were housed in groups
of two to three under standard conditions (24 °C, 12 h
light–dark cycle) with food and water available ad
libitum.
Generation of APPswe/PS1dE9/Hsp27 transgenic mice
We have previously generated transgenic mice overexpressing
the human Hsp27 protein on FVB genetic background (Tóth
et al. 2010). Transgenic DNA construct contained the human
Hsp27 cDNA driven from a cytomegalovirus (CMV) promot-
er. This transgenic line was crossed with C57BL/6 mice four
times in order to establish a Hsp27 transgenic line on a
homogenous C57BL/6 genetic background. B6C3-
Tg(APPswe/PS1dE9)85Dbo/Mmjax mice were purchased
from The Jackson Laboratory (Bar Harbor, ME, USA) and
maintained onC57BL/6 genetic background. Hsp27 transgen-
ic mice then were crossed with APPswe/PS1dE9 mice to
generate APPswe/PS1dE9/Hsp27 multiple transgenic strain.
To identify the genotype of the offsprings, polymerase chain
reaction (PCR) was performed from tail biopsies using the
following primers: 5′-GTC CCT GGATGT CAA CCA CT-3′
and 5′-GAC TGG GAT GGT GAT CTC GT-3′ for Hsp27; 5′-
GAC TGA CCA CTC GAC CAG GTT CTG-3′ and 5′-CTT
GTAAGTTGGATTCTCATATCCG-3′ for APP(Swe); and
5′-AATAGAGAACGGCAGGAGCA-3′ and 5′-GCCATG
AGG GCA CTA ATC AT-3′ for PS1dE9. The PCR amplifi-
cation was done in a MJ Research PTC-200 Thermal Cycler
using the following parameters: denaturation at 95 °C for
4 min followed by 29 cycles of denaturation at 95 °C for
1 min, annealing at 56 °C for 1 min and elongation at 72 °C
1 min, and a final extension at 72 °C for 4 min.
Western blot analysis
Expression of Hsp27 was determined from cortical and
hippocampal tissues of 7 months old transgenic mice
and wild type littermates. For ApoA1 protein level
estimation, whole brain tissue was used. Total protein
was isolated from frozen tissues homogenized in lysis
buffer (containing 50 mM Tris–HCl, 150 mM NaCl, 1 %
Triton X-100, 0.5 % Na deoxycholate, 0.1 % SDS, and
protease inhibitor), centrifuged at 10,000 rpm for 10 min at
4 °C, and the supernatant was used for western blot analysis.
Protein concentration was measured at 280 nm using a
NanoDrop spectrophotometer (NanoDrop Technologies).
Protein samples (50 μg) were separated by 10 % SDS-
PAGE (Cambrex) and transferred electrophoretically onto
Hybond-P PVDF membrane (Amersham). Membrane was
blocked for 1 h in 5 % milk powder. After a short wash in
PBS-Tween buffer, membrane was incubated with anti-Hsp27
(1:500, Stressgen, Cat No: SPA-803), anti-ApoA1 (1:250,
Rockland, Cat. No: 600-101-196), and anti-β-actin (1:1,400,
Sigma, Cat. No: A2103) antibodies overnight at 4 °C. After a
brief wash, membranes were incubated with anti-goat
(1:10,000, Jackson ImmunoResearch, Cat. No: 305-035-
003) or anti-rabbit (1:35,000, Jackson ImmunoResearch,
Cat. No: 111-035-003) secondary antibodies for 45 min at
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room temperature. Signals were developed using Luminata
Forte Western HRP Substrate (Millipore) according to the
manufacturer's instructions. Signal intensities were quantified
using ImageJ 1.45 software.
Behavioral tests
For behavioral testing, 7-month-old male mice were
used. Before starting the tests, mice were handled daily
for 2 weeks. Behavioral tests were performed between
9:00 a.m. and 4:00 p.m. Tests were recorded by video
camera, and data were analyzed by EthoVision 2002
computer-controlled video tracking system (The Noldus
Information Technology, The Netherlands).
Open field
Locomotor activity and anxiety-like behavior were studied
using open field test. Each mouse was placed in the center of
a plastic oval arena (50×70×30 cm) virtually divided into
central and peripheral areas by the software. Total distance
travelled (in centimeters), number of rearings, time spent
with grooming, and time spent in the peripheral areas were
measured. Data were collected for 5 min. All animals were
tested once.
Barnes maze test
In the Barnes maze test, using a bright light, animals
were reinforced to escape from the open platform sur-
face to a small dark chamber located under the platform
called “target box.” The experiment was performed
according to a technique published on the internet
(Sunyer et al. 2007). The maze consisted of a circular
platform (100 cm in diameter) with 20 holes (hole
diameter, 5 cm) along the perimeter. The circular open
field was elevated 90 cm from the floor. A black escape
(target) box (19×6×7 cm) was located under one of the
holes. The location of the target box was consistent for
any given mouse, but was randomized across mice. The
platform was surrounded by curtains and visual cues on
it to help the mice with orientation. Mice were placed
in the middle of the maze and were free to explore it.
The trial ended after 3 min or when the mouse entered
the escape box. When a mouse entered the escape box,
it was allowed to stay in it for 1 min. If the mouse did
not find the escape box, it was guided to it and left
inside for 1 min. One trial per day was performed for
five consecutive days. Time of latency to enter the
target box was measured. On day 8, the probe trial
was performed without the escape box to confirm that
this spatial task was acquired based on navigation using
distal-environment room cues. The trial ended after
2 min. Time of latency to reach the target hole was
measured.
Morris water maze test
For the Morris water maze test, a circular pool (130 cm
in diameter and 60 cm in height) was filled to a height
of 45 cm with water. Water temperature was maintained
between 22 °C and 23 °C, and it was made opaque by
mixing milk in it. For the invisible platform test, a
white colored platform (5 cm in diameter) was placed
at the center in one of four quadrants of the pool
(training quadrant) and submerged 1 cm below the
water surface so that it was invisible at water level.
The pool was surrounded by curtains, and different
spatial cues were attached to the curtains to help the
mice with orientation. The location of the platform was
fixed at the same quadrant while the start position of
swimming was varied. Mice were given two trials per
day for five consecutive days, during which they were
allowed to find the platform within 90 s. Once the
mouse located the platform, it was permitted to stay
on it for 10 s. If the mouse did not find the platform
within 90 s, it was guided to the platform and placed
on it for 10 s. The escape latency, the time required for
the mouse to find and climb onto the platform, was
recorded. The means of the data from each day were
used for statistics. Some of the mice have shown float-
ing behavior in the Morris water maze test. This means
that mice remained motionless most of the time during
the trial period. These mice were also very passive in
the Barnes maze test. We counted the trials when mice
showed floating/passive behavior and found that three
mice were motionless almost in the 70 % of trials;
therefore, these mice were excluded from the behavioral
tests.
Immunohistochemistry
Subsequent to the behavioral tests, mice were sacrificed by
cervical dislocation, and the brains were removed for further
studies. Frozen sections (10 μm) of the brains were
processed for immunohistochemistry. Sections were fixed
in acetone for 3 min. After a brief wash with PBS, sections
were incubated with 1.5 % H2O2 in methanol for 20 min
then with 3 % H2O2 for 20 min to block endogenous
peroxidases. PBS wash was followed by collagenase treat-
ment using 0.1 mg/ml collagenase type II (Sigma) in a
buffer containing 0.25 M NaCl, 50 mM Tris–HCl, pH 7.4,
and 1 mM EDTA at 37 °C for 5 min. After a brief wash in
PBS, sections were incubated in 5 % goat serum for 1 h at
room temperature to prevent nonspecific binding of the
antibody. Sections were then covered with anti-Aβ [1–42]
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(1:60, Invitrogen, Cat No. 700254), anti-cleaved caspase-3
(1:50, Cell Signalling, Cat. No. Asp-175), or with anti-
Hsp27 (1:50, Stressgen, Cat No: SPA-803) primary anti-
bodies overnight at 4 °C. Slides were washed with PBS,
then goat anti-rabbit secondary antibody (1:150, Jackson
ImmunoResearch, Cat. No.111-035-003) was applied for
45 min. After washing, slides were incubated with develop-
ing reagent (10 % dimethyl formamide, 10 % imidazole,
0.02 % aminoethyl carbazole, 0.04 % H2O2) at room tem-
perature until the brown color appeared (approximately
10 min). Sections were then counterstained with hematoxy-
lin solution for 2 min at room temperature followed by
washing with PBS, and they were covered with glycerol
gelatin.
For Aβ [1–42] and cleaved capase-3 antibody
stainings, 7-month-old transgenic (n=6) and wild type
(n=6) animals were used. Stained sections were
photographed using a light microscope equipped with
CCD camera, and amyloid plaques or apoptotic cells
were counted in 15 microscopic fields by two indepen-
dent individuals.
Fluoro-Jade C staining
Brains were removed, and 10-μm acetone-fixed frozen
sections were prepared. Slides were immersed into ab-
solute ethanol for 5 min, then rinsed in 70 % ethanol
for 2 min, in 30 % ethanol for an additional 2 min, and
finally in distilled water for 2 min. Sections then were
incubated in 0.06 % potassium permanganate solution
for 30 min. Following a 2-min water rinse, sections
were transferred into a 0.0004 % solution of Fluoro-
Jade C (Chemicon) fluorescent dye dissolved in 0.1 %
acetic acid. Slides were washed three times in distilled
water for 1 min. After drying, sections were cleared in
xylene for 2 min and coversl ipped with DPX
nonfluorescent mounting media. Degenerating neurons
emitting green fluorescence were visualized under
Nikon Eclipse E600 fluorescent microscope using a
520-nm fluorescein filter set. Six 7-month-old animals
from each group were selected, and two slides of each
animal's brain were stained using Fluoro-Jade C dye.
On each slide, 15 digital photographs were taken, and
degenerating neurons were counted by two independent
individuals.
Hippocampal slice electrophysiology
Following standard procedures, 400-μm-thick transverse
hippocampal slices were prepared from the brain of 7-
month-old mice using a McIlwain tissue chopper (Campden
Instruments, Loughborough, UK). Slices were incubated in
standard artificial cerebrospinal fluid (ACSF) at ambient
temperature for 60 min, which was constantly gassed with
95 % O2–5 % CO2. ACSF contained (millimolar) NaCl,
130; KCl, 3.5; CaCl2, 2; MgCl2, 2; NaH2PO4, 0.96;
NaHCO3, 24; D-glucose, 10 (pH 7.4). Individual slices were
transferred to a 3D-MEA chip with 60 tip-shaped and
60-μm-high electrodes spaced by 200 μm (Ayanda
Biosystems, S.A., Lausanne, Switzerland). The slice was
continuously perfused with oxygenated ACSF (1.5 ml/min
at 36 °C) during the whole recording session. Data were
recorded by a standard, commercially available MEA setup
(Multi-Channel Systems MCS GmbH, Reutlingen, Germa-
ny). The Schaffer collateral was stimulated by injecting a
biphasic voltage waveform (−100/+100 μs) through one
selected electrode at 0.033 Hz. Care was taken to choose
the stimulating electrode in the same region from one slice
to the other. The peak-to-peak amplitudes of fEPSPs at the
stratum pyramidale and stratum radiatum of CA1 were
analyzed. After a 30-min incubation period, the threshold
and the maximum of stimulation intensity for evoked re-
sponses was determined. For evoking responses, 30 % of the
maximal stimulation intensity was used.
Following a stable 10-min control sequence, the stimulus
intensity was continuously increased from 400 to 3,200 mV
with 400 mV steps (input/output curve). Paired-pulse pro-
tocol consisted of two stimulation pulses injected with
interstimulus intervals of 20, 50, 200, and 500 ms with
0.033 Hz. Three data points were obtained at every stimu-
lation intensity/interstimulus intervals at the input/output
curve and paired-pulse protocol. LTP was induced using a
theta-burst stimulation (TBS) pattern applied at the maxi-
mum stimulation intensity. TBS comprised a train with ten
bursts given at 5 Hz per train and four pulses given at
100 Hz per burst.
RNA extraction and quantitative real-time PCR
For quantitative real-time PCR (Q-PCR), 6-month-old
Hsp27 transgenic (n=3) and wild type mice (n=3) were
used. Total RNA was extracted from whole brain using
Trizol reagent (Invitrogen), according to the manufacturer's
protocol. RNA samples then were cleaned using
NucleoSpin RNA Clean-up columns (Macherey-Nagel)
and treated with DNaseI (Macherey-Nagel) for 30 min.
First-strand cDNA was synthesized by reverse transcription
(5 μg RNA/30 μl reaction volume) using High-Capacity
cDNA Archive kit (Applied Biosystems). The temperature
profile of the reaction was as follows: 10 min at room
temperature, 2 h at 37 °C, 5 min on ice, and finally,
10 min at 75 °C.
Q-PCR was performed on a RotorGene 3000 instrument
(Corbett Research, Sydney, Australia) using gene-specific
primers listed in Table 1. The cDNA was diluted 1:20, and
9 μl of this mix was used as a template in the reaction.
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Reactions were performed in a total volume of 20 μl
containing 10 μl of FastStart SYBR Green Master mix
(Roche) and 5 mM of each primer. The amplification was
carried out with the following cycling parameters: 15 min
heat activation at 95 °C, followed by 45 cycles denaturation
at 95 °C for 25 s, annealing at 60 °C for 25 s, and extension
at 72 °C for 20 s. Fluorescent signals were collected after
each extension step at 72 °C. Relative expression ratios were
normalized to β-actin.
Statistical analysis
All data obtained in this experiment were expressed as
mean ± SEM. Statistical analysis was performed by one-way
analysis of variance (ANOVA) followed by Fisher's post hoc
test using OriginPro8 software. Electrophysiological data
were analyzed by two-way ANOVA followed by Tukey's post
hoc test. The level of statistical confidence was set at p<0.05.
Results
Generation of transgenic mice
Transgenic mice overexpressing the human Hsp27 protein
were generated in our laboratory as described earlier (Tóth
et al. 2010). By crossing the human Hsp27 overexpressing
mice with the APPswe/PS1dE9 mouse strain, we generated
a triple transgenic mouse strain. The APPswe/PS1dE9 strain
(The Jackson Laboratory, Bar Harbor, ME, USA) is a wide-
ly used mouse model of AD (Jankowsky et al. 2004,
Reiserer et al. 2007, Hamilton and Holscher 2012), and it
shows several symptoms of the disease including impaired
spatial learning, reduced long-term potentiation, widespread
amyloid deposition, and mild neurodegeneration (The Jackson
Laboratory (2013)) (http://jaxmice.jax.org/strain/004462.html).
First, cerebral expression of the Hsp27 transgene was
investigated. Using western blot analysis, robust expression
of human Hsp27 was detected in the cortical and hippocampal
tissues of Hsp27 and triple transgenic (AD/Hsp) brains, while
no expression was found in wild type and APPswe/PS1dE9
(AD) littermates (Fig. 1a). Hsp27 expression was also
confirmed in the brain of Hsp27 and APPswe/PS1dE9/Hsp27
animals using immunohistochemical staining (Fig. 1b). While
Hsp27 antibody stained hippocampal tissues of Hsp27 trans-
genics homogeneously, it showed a spotted, plaque-like
staining pattern in the hippocampal region of APPswe/
PS1dE9/Hsp27 brains (Fig. 1c).
Behavioral tests
Seven-month-old male mice were divided into three exper-
imental groups: an AD mouse model group (APPswe/PS1dE9,
n=11), an APPswe/PS1dE9/Hsp27 triple transgenic group (n=
12), and a wild type group (n=9).
Locomotor activity
First, locomotor activity (total distance travelled), explor-
atory behavior (number of rearings), and anxiety (time spent
on the periphery, time spent with grooming) were recorded
using open field test. There was no significant difference
between groups in these behavioral features (total distance
travelled, p=0.25; rearings, p=0.34; time spent on periph-
ery, p=0.33; grooming, p=0.64).
Barnes maze test
Spatial learning and memory were tested using Barnes
maze and Morris water maze tests. Both tests are based
on spatial navigation, and the performance of the ani-
mals depends on hippocampal function (Kennard and
Woodruff-Pak 2011). In Barnes maze test, APPswe/PS1dE9
mice spent more than 130 s with searching the escape box on
Table 1 List of Q-PCR primers used in this study
Gene Forward primer Reverse primer
Amyloid precursor protein (APP) TACTGCATGGCGGTGTGT CGTGGGAAGTTTATCAGGATCT
Apolipoprotein-AI (ApoAI) TATGTGGATGCGGTCAAAGA TGAACCCAGAGTGTCCCAGT
Apolipoprotein-D (ApoD) GAAGGCTTTTACAGGCTCCA GGCCAGGAACATCAGCAT
Apolipoprotein-E (ApoE) CAATTGCGAAGATGAAGGCTC TAATCCCAGAAGCGGTTCAG
Nitric oxide synthase-1 (Nos1) CATCAGGCACCCCAAGTT CAGCAGCATGTTGGACACA
Nitric oxide synthase-3 (Nos3) CCAGTGCCCTGCTTCATC GCAGGGCAAGTTAGGATCAG
LDL receptor-related protein-1 (Lrp1) ACCACCATCGTGGAAAATG GTCCCAGCCACGGTGATA
LDL receptor-related protein-2 (Lrp2) GATGGATTAGCCGTGGACTG TCCGTTGACTCTTAGCATCTGA
Low-density lipoprotein receptor (LDLr) CAAGAGGCAGGGTCCAGA CCAATCTGTCCAGTACATGAAGC
Heat shock protein 90 (Hsp90) GTCTCGTGCGTGTTCATTCA CATTAACTGGGCAATTTCTGC
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each day of the training period. In contrast, wild type and
APPswe/PS1dE9/Hsp27 mice learned soon to find the escape
hole as indicated by the reduction of escape latency. On the
fourth day, mice from the wild type group spent 76 s with
searching and performed significantly better than
APPswe/PS1dE9 mice (140 s; p<0.05; Fig. 2a). However,
there was no significant difference between the performance of
wild type and APPswe/PS1dE9/Hsp27 mice. On the fifth day,
the escape latency of the wild type and APPswe/PS1dE9/Hsp27
groups were 92 and 72 s, respectively, performing significantly
better then APPswe/PS1dE9mice (169 s; p<0.01 and p<0.001),
and again, there was no significant difference between
APPswe/PS1dE9/Hsp27 and wild type groups (Fig. 2a). The
probe trial was performed 3 days after the last training session.
The result of the probe trial was similar to the previous trial; wild
type and APPswe/PS1dE9/Hsp27 mice found the correct target
hole within 50 and 41 s, respectively, and these were signif-
icantly shorter compared to APPswe/PS1dE9 mice (93 s; p<
0.05 and p<0.01). No statistical difference was observed
between wild type and APPswe/PS1dE9/Hsp27 groups
(Fig. 2b).
Morris water maze test
Spatial learning was also tested using Morris water maze to
confirm the result of Barnes maze test. On the third day,
wild type mice find the escape platform in 41 s on average,
and this was significantly shorter compared to APPswe/PS1dE9
group (76 s, p<0.01; Fig. 2c). On the fourth day, the escape
latency of the wild type andAPPswe/PS1dE9/Hsp27 groupswas
52 and 50 s, respectively, performing significantly better than
APPswe/PS1dE9 mice (74 s; p<0.05). There was no difference
Fig. 1 a Detection of human
Hsp27 expression in the
hippocampus and cortex of wild
type (Wt), APPswe/PS1dE9
(AD), APPswe/PS1dE9/Hsp27
(ADHsp), and Hsp27
transgenic mice (Hsp27) using
western blot analysis. b Hsp27
immunostaining of brain
sections of 7 months old wild
type (Wt), Hsp27 transgenic
(Hsp27), APPswe/PS1dE9, and
APPswe/PS1dE9/Hsp27 mice.
Brown staining indicates
human Hsp27
immunoreactivity (black
arrows). Nuclei were
counterstained with
hematoxylin. Scale bar
indicates 100 μm. c Higher
magnification of the
hippocampal region of Hsp27
transgenic and APPswe/
PS1dE9/Hsp27 mice stained by
anti-Hsp27 antibody. Black
arrows indicate a plaque-like
staining of Hsp27. Scale bar
represents 100 μm
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between the performance of APPswe/PS1dE9/Hsp27 and wild
type groups (Fig. 2c). Interestingly, on the last day of training
sessions, there was no statistical difference between groups, and
the performance of most animals has declined.
Hippocampal slice electrophysiology
Hippocampal function was studied using paired-pulse facil-
itation (PPF) and long-term potentiation (LTP). Excitability
Fig. 2 Assessment of learning
and memory using behavioral
assays. Cognitive behavior of
7 months old wild type (WT,
n=9), APPswe/PS1dE9 (n=11),
and APPswe/PS1dE9/Hsp27
(n=12) transgenic mice were
compared. Escape latency in
seconds during training session
(a) and probe test of the Barnes
maze test (b). Escape latency in
seconds in Morris water maze
test (c). Mean ± SEM is shown;
*p<0.05; **p<0.01;
***p<0.001
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of neurons was studied at stimulation intensity of 0.4, 0.8,
1.2, 1.6, 2.0, 2.4, 2.8, and 3.2 V. Slices prepared from brains
of AD model (APPswe/PS1dE9) mice showed an elevated
fEPSP increase at the same stimulus intensity compared to
control, indicating an increased excitability of neurons (p≤
0.05, two-way ANOVA; Fig. 3a). This increased synaptic
excitability was normalized in APPswe/PS1dE9/Hsp27
mice (Fig. 3a). However, paired-pulse facilitation did not
differ significantly among the groups, indicating that pre-
synaptic function was unaffected by the genotype (Fig. 3b).
LTP is a cellular correlate of learning and memory. We
found that LTP was impaired in the APPswe/PS1dE9 group
(125±6 % vs. 154±6 % in the wild type, p≤0.05), but this
was partially rescued in the APPswe/PS1dE9/Hsp27 geno-
type mice (144±8 %; Fig. 3c, d).
Amyloid staining
Amyloid plaque formation was studied by immunostaining of
frozen brain sections of 7-month-old transgenic and wild type
mice using anti-Aβ [1–42] antibody. Numerous amyloid de-
posits were observed in the hippocampus and cortex of
APPswe/PS1dE9 transgenic animals (0.99/field of view and
1.08/field of view, respectively), in contrast to wild type
animals (0.02/field of view in the hippocampus and 0.06/field
of view in the cortex; Fig. 4a, b). Amyloid plaques were
detected in APPswe/PS1dE9/Hsp27 brains as well (0.69/field
of view in the hippocampus and 0.78/field of view in the
cortex; Fig. 4a, b); however, the number of plaques was
significantly less in both regions than in APPswe/PS1dE9
group (p<0.05; Fig. 4c), indicating that Hsp27 might prevent
Fig. 3 Electrophysiological recordings on hippocampal slices from
7 months old mice. a Neuronal excitability of transgenic mice at
different stimulation intensities. Data was analyzed by two-way
ANOVA followed by Tukey's test. Asterisk denotes p<0.05. b Assess-
ment of synaptic function in wild type (Wt, n=8), APPswe/PS1dE9
(AD, n=6), and APPswe/PS1dE9/Hsp27 (ADHSP, n=7) mice using
PPF. There was no significant difference in PPF values of different
genotypes. c TBS induced LTP in transgenic (AD and ADHSP) and
wild type mice. d Bar graph shows the fEPSP amplitude means of the
last 5 min of LTP. Asterisk denotes p≤0.05 analyzed by ANOVA and
post hoc Bonferroni test
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amyloid aggregation and plaque formation, or it can facilitate
amyloid clearance and degradation in the brain.
Neuronal apoptosis
We used anti-active caspase-3 antibody and Fluoro-Jade C
stainings tomonitor apoptosis and neurodegeneration in the brain
of 7-month-old transgenic mice. Activation of effector caspase-3
molecules triggers the activation of caspase cascade, which
eventually leads to apoptosis of the cells (Boatright and Salvesen
2003). Fluoro-Jade C is an anionic fluorochrome, which sensi-
tively and specifically binds to degenerating neurons (Schmued
et al. 2005). We detected significantly increased number of
apoptotic cells (Fig. 5a) and degenerated neurons (Fig. 5b) in
the hippocampal as well as cortical regions of APPswe/PS1dE9
and APPswe/PS1dE9/Hsp27 transgenic brains compared to wild
type animals (p<0.001); however, there was no statistical differ-
ence between AD model mice and AD model mice expressing
Hsp27.
Gene expression analysis of Hsp27 transgenic mice
Results obtained above indicated that Hsp27, as a molecular
chaperone, might have a role in inhibition of amyloid
Fig. 4 Immunostaining of hippocampal (a) and cortical (b) amyloid
plaques in 7 months old APPswe/PS1dE9, APPswe/PS1dE9/Hsp27
transgenic, and wild type (Wt) mice. Arrows indicate the presence of
amyloid deposits. c Number of Aβ deposits/field of view in wild type
(Wt, n=6), APPswe/PS1dE9 (n=6), and APPswe/PS1dE9/Hsp27 mice
(n=6; mean ± SEM is shown; *p<0.05)
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Fig. 5 Quantitative comparison of apoptotic cell (a) and degenerating
neuron (b) numbers in the hippocampus and cortex of 7 months old
wild type (Wt, n=6), APPswe/PS1dE9 (n=6), and APPswe/PS1dE9/
Hsp27 (n=6) mice. Apoptotic cells were detected by anti-active
caspase-3 antibody staining, while degenerating neurons were visual-
ized using Fluoro-Jade C staining. Mean ± SEM is shown
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accumulation/deposition or in enhanced amyloid clearing
and degradation. In order to clarify its molecular role, we
monitored the gene expression of several genes potentially
involved in β-amyloid metabolism such as APP, ApoA1,
ApoD, ApoE, LDLr, Lrp1, Lrp2, Hsp90, and neurodegeneration
(NOS1 and NOS2) in the cortex of Hsp27 transgenic mice using
Q-PCR. Primers used in this study are listed in Table 1. The
expression level of ApoD and Lrp2 was slightly increased
(128 % and 128 %, respectively), in the brain of Hsp27 trans-
genic mice compared to wild type controls (100 %), whereas
there was no change in the mRNA level of APP, ApoE, LDLr,
Lrp1, Hsp90, NOS1, and NOS3. Rather surprisingly, cortical
expression of ApoA1 was reduced by half in Hsp27 transgenics
versus wild type mice (Fig. 6a). Decreased ApoA1 expression in
Hsp27 transgenic mice was further confirmed using western
blotting. ApoA1 protein level was reduced in Hsp27 transgenic
mice (61.1%), but slightly elevated inADmodelmice (126.7%)
compared to wild types (100 %). However, AD mice
overexpressing human Hsp27 protein possessed similar ApoA1
protein level than wild type mice, indicating that Hsp27
influenced ApoA1 expression (Fig. 6b, c).
Discussion
In this study, we investigated the effects of small heat shock
protein, Hsp27, on the development of AD-related pheno-
types in transgenic mice. For this purpose, we used
APPswe/PS1dE9 transgenic strain. These mice develop sev-
eral AD-related phenotype including amyloid-beta deposits,
abnormal spatial memory, axon degeneration, and synapse
loss (The Jackson Laboratory (2013)) (http://jaxmice.jax.org/
strain/004462.html). We overexpressed the human Hsp27
protein in AD model mice and monitored learning and
memory, synaptic function, amyloid deposition, and neuronal
apoptosis in the triple transgenic mice.
Decline of the short-term memory is among the primary
symptoms in AD patients. We found that spatial learning
was impaired in APPswe/PS1dE9 mice as the time required
to find the escape hole in Barnes maze test, or the platform
in Morris water maze test was significantly longer compared
to wild type mice. However, the performance of
APPswe/PS1dE9/Hsp27 group was similar to the wild type
group in both tests, which suggests that overexpression of
Hsp27 protein ameliorates learning and memory deficits.
We have also found that synaptic excitability was in-
creased in AD model mice, but this was normalized by
Hsp27 overexpression. This is in accordance with earlier
findings of others who demonstrated that seizure suscepti-
bility is increased in AD model mice (Westmark et al. 2008;
Vogt et al. 2009), and heat shock proteins can moderate
chemically induced seizures (Akbar et al. 2003; Ekimova
et al. 2010). LTP, a cellular correlate of learning and
memory (Bliss and Colingridge 1993), was also investigated
on hippocampal slices. Previously, it was demonstrated that
soluble oligomers of Aβ are able to inhibit LTP and cause
learning and memory deficit (Haas and Selkoe 2007; Bozso
et al. 2010). Our results have shown that LTP was impaired
in APPswe/PS1dE9 mice indeed, but it was normalized
upon Hsp27 overexpression. There is substantial evidence
from transgenic mouse models that intracellular Aβ initiates
cellular dysfunction, synaptic, electrophysiological, and be-
havioral changes before it accumulates in extracellular
plaques (Moechars et al. 1999; Kumar-Singh et al. 2000;
Mucke et al. 2000). The toxic Aβ molecules (either soluble
oligomers or fibrillar forms) might initiate a cascade, which
finally leads to neuronal dysfunction. Therefore, inhibition
of Aβ oligomerization and deposition or enhanced clear-
ance of Aβ might play a crucial role in the prevention and
therapy of AD. We have found a significantly lower level of
amyloid deposition in the brain of AD/Hsp27 animals com-
pared to the AD group, indicating that Hsp27 is somehow
involved in these processes. In AD, heat shock protein
expression is associated with Aβ deposition and neurofi-
brillary tangles, and recent findings suggest that Hsps pre-
vent the accumulation of Aβ (Abdul et al. 2006; Evans et al.
2006). Wilhelmus et al. (2006) demonstrated that Hsp20,
Hsp27, and αB-crystallin bind strongly to Aβ and inhibit its
aggregation. Furthermore, Hsp20, Hsp27, and αB-crystallin
inhibited cerebrovascular Aβ toxicity, probably by reducing
the accumulation of Aβ at the cell surface.
Aggregated forms of Aβ might lead to neurodegeneration
through different pathways. Several studies have shown that
chronic inflammatory response to deposited amyloid resulted
in neurodegeneration (Akiyama et al. 2000; Wyss-Coray and
Mucke 2002). Although heat shock proteins have protective
effects in neurodegenerative disease models, the molecular
basis of this protection is not fully understood. It is likely that
heat shock proteins have effect at several levels, and their
neuroprotective function might not be linked exclusively to
their effect on protein aggregation (Muchowski and Wacker
2005). For example, Hsps are known to reduce oxidative
stress and mediate apoptotic pathway. They can also facilitate
proteasomal degradation, which might help in Aβ clearance.
However, the exact molecular mechanisms of Aβ-induced
neurotoxicity are not fully known. Thesemechanisms are very
diverse, and probably include the increased production of
reactive oxygen species (ROS), altered calcium homeostasis,
and enzyme activities. Several lines of evidence are available
suggesting that Aβ can interact with artificial and biological
membranes altering their fluidity. Altered membrane fluidity
can influence the function of other membrane components.
Certain studies suggest that the insertion of Aβ into the
plasma membrane triggers different events catalyzed by per-
turbation of the conformation of membrane proteins, which
finally leads to neurotoxicity (Kanfer et al. 1999). This
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hypothesis suggests that the neurotoxic cascade of Aβ is
initiated in the cell membrane. It is also important, that α-,
β-, and γ-secretases are associated with cellular membranes;
thereby, their function, such as APP processing, strongly de-
pends on membrane fluidity. Peters et al. (2009) showed that
oligomeric Aβ can reduce membrane fluidity, which in turn
stimulates the amyloidogenic processing of APP. Several
studies suggest that a subpopulation of Hsps is present either
on the surface or within the cellular membranes, and they have
been shown to modulate major attributes of the membrane
lipid phase such as fluidity and permeability. By stabilizing
the membrane, Hsps can restore membrane functionality dur-
ing stress conditions (Horváth et al. 2008). We can suppose
that Hsp27 also can interact with and stabilize cellular mem-
branes; thereby, it can diminish the level of Aβ-induced
neurotoxic cascade or, moreover, the production of Aβ. The
generation of ROS is also a crucial factor in the molecular
mechanisms of Aβ-induced neurotoxicity. Lipid peroxidation,
and protein and DNA oxidation are remarkable in the brain of
AD patients, and Aβmight have a central role in the induction
of these processes (reviewed in Butterfield et al. 2001). Hsp27
has a protective effect in oxidative stress; thereby, Hsp27
might eliminate the neurotoxicity of Aβ at least in part due
to this property.
To know more about the role of Hsp27 in amyloid me-
tabolism—whether it inhibits APP production or enhances
amyloid clearance/degradation—we performed gene expres-
sion analysis. No decrease in APP production was detected;
however, a subtle elevation of ApoD and LRP1 protein
levels in Hsp27 transgenic brains was observed. Although
ApoD and LRP1 proteins have important roles in
neuroprotection and Aβ clearance, respectively (Terrise at
al. 1998; Kalman et al. 2000; Thomas et al. 2001; Muffat et
al. 2008; Kang et al. 2000), we do not consider that the mild
changes obtained in their expression would be sufficiently
enough to lead to efficient reduction of amyloid plaque
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Fig. 6 Gene expression
profiles of different genes
involved in amyloid
metabolism in Hsp27
transgenic mice using Q-PCR
analysis (a). Data was
normalized to the endogenous
β-actin, then expressed as a
percent of wild type expression
(100 %). b Representative
western blot of ApoA1
expression in Hsp27 transgenic
(Hsp27), wild type (Wt), AD
model (APPswe/PS1dE9), and
AD/Hsp27 (APPswe/PS1dE9/
Hsp27) brains. c Statistical
analysis of western blot
experiment. Hsp27 transgenic
(n=5), wild type (Wt, n=6),
AD model (n=5), and AD/Hsp
triple transgenic mice (n=6)
were compared
Hsp27 improves neuronal function in AD mice 769
numbers. Now it is widely accepted that ApoD is elevated in
many neuropathological conditions, including Alzheimer's
disease, Parkinson's disease, stroke, schizophrenia, and bi-
polar disorder. It was also demonstrated that in Drosophila,
overexpressed ApoD had a protective effect against oxida-
tive stress and heat shock (Muffat et al. 2008). In vitro LDL
receptor-related protein 1 (LRP1) mediates the clearance of
both Aβ 40 and Aβ 42 through a bona fide receptor-
mediated uptake (Kang et al. 2000); therefore, LRP and its
ligand ApoE have been proposed to be a clearance pathway
for Aβ. At the same time, the role of ApoA1 in amyloid
metabolism and AD pathology is controversial. Although it
has been shown that ApoA1 inhibits Aβ aggregation in vitro
(Koldamova et al. 2001), in vivo studies resulted different
results. Crossing of ApoA1 null mice with AD model mice
resulted no change in amyloid deposition in the brain (Fagan
et al. 2004). Similarly, when ApoA1 overexpressing mice
were crossed with AD model mice, no alteration in amyloid
metabolism was observed (Lewis et al. 2010). Our result
presented here shows that expression of ApoA1 was
downregulated in Hsp27 transgenic mice, indicating that
Hsp27 might have a role in the regulation (directly or
indirectly) of ApoA1 expression.
Taken together, further investigations are necessary to
reveal the exact molecular pathways involved in
neuroprotective function of Hsp27.
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